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ABSTRACT 
Elastic fibers are components of the extracellular matrix (ECM) that contribute resilience 
to tissues and bind and regulate transforming growth factor beta (TGFβ). Elastin gene (ELN) 
mutations cause several phenotypes including Williams-Beuren Syndrome (WBS), supravalvular 
aortic stenosis (SVAS) and autosomal dominant cutis laxa (ADCL). This work focused on the 
molecular consequences of the ELN gene mutations in ADCL and SVAS.  
         ADCL is characterized by loose and inelastic skin, pulmonary emphysema, aortic root 
dilation, and peripheral pulmonary aortic stenosis. Our goal was to evaluate the impact of ELN 
mutations on TGFβ signaling and molecular pathology of ADCL. Dermal fibroblasts from four 
patients with ELN mutations in exon 34 or exon 30 and controls were used. Increased 
intracellular TGFβ signaling was found in patients with exon 30 mutations, despite unchanged 
extracellular TGFβ activity. TGFBR1 levels were increased at the protein and the RNA level. 
Patients with exon 34 mutations had normal TGFβ signaling. Our results indicate mutation-
specific TGFβ signaling changes in ELN-related cutis laxa patients, which may influence to 
disease severity. Elastin assay showed decreased elastin deposition in ADCL cells and long-term 
TGFβ treatment improved elastin deposition. Semi-quantitative RT-PCR experiments showed 
increased expression of the mutant compared to the wild-type allele in 
ADCL cells under baseline conditions. Long-term TGFβ treatment normalized this allelic 
imbalance in expression. Therefore, we conclude that increased TGFβ signaling is a protective 
mechanism in ADCL at the molecular level. 
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SVAS is characterized by narrowing of the ascending aorta. An SVAS family with a 
duplication in the ELN gene was analyzed genetically and functionally. Gene-dosage analysis 
showed that a tetranucleotide repeat in intron 1 was within the duplicated region. RT-PCR of 
pre-mRNA showed that a SNP in intron 23 of the mutant allele was not expressed. Decreased 
elastin deposition was found in affected individuals, supporting that this partial duplication 
yielded a null allele. 
Uncovering the nature of connections between elastin and TGFβ may help developing 
treatments for cutis laxa. Our findings are relevant to complex diseases characterized by elastin 
degradation and TGFβ dysregulation, including aneurysms and chronic obstructive pulmonary 
disease that have major public health impact. 
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1.0  INTRODUCTION 
1.1 EXTRACELLULAR MATRIX 
The extracellular matrix (ECM) acts as a scaffold that supports cells in all tissues and organs. 
The ECM is comprised of a fibrous material, including collagen fibers, microfibrils and elastic 
fibers and ground substance surrounding the fibers, including proteoglycans and glycoproteins. 
The ECM has roles in cell-cell communication, cell proliferation, migration, cell differentiation, 
development, and survival. The ECM is also crucial for the storage of growth factors, cytokines 
and ECM-remodeling enzymes (Naba et al., 2012).  
Collagen fibers are a major component of ECM, which provide tensile strength and have 
roles in cell adhesion, chemotaxis and migration and tissue morphogenesis (Kadler et al., 2007). 
Elastic fibers complement collagen fibers to provide resilience to the tissues, whereas 
glycoproteins contribute to tissue cohesiveness. Proteoglycans are bulky polysaccharides 
(glycosaminoglycans, GAGs) covalently attached to relatively smaller core proteins, which 
counteract compressive forces (Gandhi and Mancera, 2008) and are important in cell signaling 
and wound healing (Gandhi and Mancera , 2008).  
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1.1.1 ELASTIC FIBERS 
Elastic fibers are major insoluble components of ECM that are vital for connective tissues 
including large arteries, skin, lung, ligaments, and auricular cartilage (Figure 1.3). Elastic fibers 
show tissue-specific and morphologically distinct networks based on the elasticity requirements 
of tissues (Baldwin, Simpson et al. 2013). The thick elastic fiber networks in the reticular dermis 
and thin fibers in the papillary dermis provide skin elasticity. Highly branched networks of 
elastic fibers that provide respiratory expansion and recoil are main providers of pulmonary 
elasticity. Arterial elastic fibers form lamellar layers for vascular elasticity (Kielty 2006).  Elastic 
fibers also have a crucial role in vascular smooth muscle cell differentiation during arterial 
development (Karnik et al., 2003). In addition, elastic fibers also regulate the bioavailability of 
TGFβ family (Nistala et al., 2010). 
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1.1.1.1 Composition of elastic fibers 
Elastic fibers are composed of two primary components: an inner core of cross-linked elastin and 
microfibrils (Baldwin et al. 2013). In addition, several ‘accessory’ molecules interact with 
microfibrils and elastin as well as its precursor, tropoelastin (Baldwin et al. 2013). 
1.1.1.2 Elastin 
Elastin is the key insoluble protein in the elastic fibers (90%) (Kielty, 2006) and it is the primary 
provider of elasticity and resilience. At first, elastin is synthesized as tropoelastin, a precursor 
protein of 60-70 kDa secreted from elastogenic cells such as fibroblasts, smooth muscle cells 
(SMCs) and auricular chondrocytes (Baldwin et al. 2013).  Its primary structure includes valine-, 
proline-, and glycine-rich hydrophobic domains and hydrophilic cross-linking domains, which 
are rich in lysine and alanine (Figure 1.1). Hydrophobic domains are important during the self-
aggregation of tropoelastin by coacervation (Vrhovski et al., 1997). Coacervation brings 
tropoelastin monomers together, and their association is stabilized by cross-links, known as 
desmosines or isodesmosines (Viglio et al., 2007). The asymmetric structure of elastin includes 
an N-terminal part that provides spring-like properties and a C-terminal part that has a role in cell 
adhesion by αvβ3 integrin and cell surface proteoglycans (Bax et al.  2009). The human elastin 
gene is localized to chromosome 7q11.2 and has 34 exons spanning 45 kb of the genome (Fazio 
et al., 1998). Human elastin primary transcript undergoes alternative splicing leading to many 
different mRNA isoforms.  
Elastin is a crucial protein in the aorta and great arteries. ELN-/- mice die immediately 
after birth due to the vascular obstruction, caused by an enhanced proliferation of smooth muscle 
cells (Li et al., 1998). In contrast, ELN+/- mice survive until adulthood and show systemic 
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hypertension, enhanced a number of elastic lamellae, the elastin layers associated with SMCs (Li 
et al., 1998; Faury et al., 2003) and a thinner wall of blood vessels (Wagensil et al., 2005). 
 
 
Figure 1.1 Schematic representation of human tropoelastin 
The domain organization of tropoelastin is shown with the keys for domain types. GAGs: 
glycosaminoglycan 
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1.1.1.3 Fibrillin 
Fibrillins are the main components of the microfibril scaffold, which provide a template for 
elastin deposition. Fibrillins are large (350 kDa) extracellular cysteine-rich glycoproteins, and 
the fibrillin family has three fibrillin genes in humans, fibrillin-1, fibrillin-2 and fibrillin-3 (Piha-
Gossack, 2012). Each fibrillin gene has 43 calcium-binding epidermal growth factor-like 
(cbEGF) domains, five EGF-like domains, seven eight-cysteine-containing (TB) motifs and two 
hybrid domains with similarities to TB and cbEGF-like domains (Figure 1.2) (Baldwin et al. 
2013). 
The most predominant fibrillin is fibrillin-1, and its gene is localized on chromosome 
15q21.1. Fibrillin-1 is expressed all the time, responsible for microfibril homeostasis; however, 
fibrillin-2 and fibrillin-3 are mostly expressed during development (Charbonneau et al., 2003; 
Zhang et al., 1994; Corson et al., 2004; Sabatier et al., 2011).  The interior parts of microfibrils 
with fibrillin-1 might be made from fibrillin-2 (Charbonneau et al., 2010). Fibrillin-1 is indicated 
to have crucial roles in vascular development in mouse models. FBN-1-/- mice die from an aortic 
aneurysm, but FBN-2-/- mice have normal vascular development (Carta et al., 2006). 
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Figure 1.2 Schematic representation of fibrillin-1 
The localization of binding sites for key proteins is shown above and below fibrillin-1 as color-
coded horizontal lines. HSPG: heparan sulfate proteoglycan. 
 
 
 
 
 
 
 
 7 
1.1.1.4 Accessory molecules associated with microfibrils and elastic fibers 
Several microfibril and elastic fiber associated accessory molecules have been identified based 
on functional biochemical and morphological analyses. The microfibril-associated molecules 
include latent TGFβ binding proteins (LTBPs), a disintegrin and metalloprotease with 
thrombospondin type-I motif (ADAMTS) and ADAMTS-like proteins, and microfibril-
associated glycoproteins (MAGPs) and elastic-fiber associated molecules include fibulin 3-5 and 
lysyl oxidase (LOX) and lysyl oxidase-like 1 (LOXL1) proteins (Baldwin et al. 2013).  
The ADAMTS superfamily consists 19 zinc metalloproteases and 7 ADAMTS-like 
(ADAMTSL) proteins, which have roles in ECM deposition, microfibril biology and 
morphogenesis (Apte et al., 2009). ADAMTSL members only have multiple thrombospondin 
type 1 repeats (TSRs), whereas ADAMTS family members have disintegrin-like and a cysteine-
rich modules in addition to a single TSR (Baldwin et al., 2003). ADAMTS-10 and ADAMTSL 
2-6 are important in microfibril biology (Hubnacher et al., 2011). The binding of fibrillin-1 and 
fibrillin-2 to ADAMTSL-5 help colocalization with microfibrils (Bader et al., 2012).  
MAGP-1 can associate with elastin and possibly help elastin deposition on microfibrils 
(Jensen et al., 2001; Rock et al., 2004) and can also regulate of TGFβ signaling by binding TGFβ 
and BMP-7 (Weinbaum et al., 2008). MAGP-1 might also affect fibronectin-mediated 
microfibril deposition by interacting with fibronectin (Werneck et al., 2008). MAGP-2 was 
found to colocalize with microfibrils in several tissues (Lemaire et al., 2007; Gibson et al., 1998; 
Penner et al., 2002; Hanssen et al., 2004), however, MAGP1-/- mice demonstrated normal 
microfibrils and elastin, indicating that it is not essential for elastic fiber assembly (Craft et al., 
2010). Overexpression of MAGP-2 can enhance elastic fiber formation (Lemaire et al., 2007). 
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The LTBPs (LTBPS 1-4) are large glycoproteins, and their multi-domain structure 
includes cbEGF and TB domains similar to fibrillins. LTBPs 1-4 are expressed in several tissues 
including the heart, lung, and ovary (Piha-Gossack et al., 2012; Todorovic et al., 2005). The third 
TB domains of LTBPs bind the small latent complex (SLC) of TGFβ comprising the latency-
associated peptide (LAP) and the tightly but non-covalently bound TGFβ growth factor  (Gleizes 
et al., 1996; Saharinen et al., 1996) to form the large latent complex (LLC) and also regulate the 
bioavailability of TGFβ (Todorovic et al., 2005; Gleizes et al., 1996; Saharinen et al., 1996). The 
interaction between fibrillin-1 and the fourth TB domain of LTBPs ensures the sequestration of 
the LLC to fibrillin microfibrils, which therefore themselves regulate TGFβ activity too 
(Saharinen et al., 1996). Fibronectin is needed for LTBP-1 and LTBP-4 deposition into the ECM 
(Zilbergberg et al., 2012; Reber-Muller et al., 1995; Kantola et al., 2008). 
Fibulins are extracellular glycoproteins including fibulin 1-5 (Yanagisawa et al., 2010). 
Fibulin-4 and fibulin-5 can interact with LOX and LOX-like (LOXL) enzymes and fibrillin-1, 
and these interactions were implicated in elastin crosslinking and deposition onto microfibrils 
(Baldwin et al., 2013). Fibulin-3, -4 and -5 have important roles in the assembly of elastic fibers 
(Yanagisawa et al, 2010; Kobaya et al., 2007). In addition, one likely role of fibulin-4 is to help 
sequestration of LTBPs (Ono et al., 2009). Fibulin-5 is a regulator of the deposition of elastin 
onto microfibrils (Zheng et al., 2007). 
LOX family has five members including LOX and LOXL1-4 (Molnar et al., 2003). They 
oxidatively deaminate the peptidyl lysine residues in elastin to form allysine, a reactive aldehyde. 
Three allysine and one lysine side chains spontaneously condense to form tetrafunctional 
desmosine and isodesmosine crosslinks to form insoluble elastin (Molnar et al., 2003). The N- 
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terminal regions of LOX family members provide specificity to the extracellular LOX enzymes 
(Baldwin et al., 2013). 
1.1.1.5 Assembly of elastic fibers 
Fibronectin acts as a platform for microfibril deposition (Kinsey et al., 2008; Sabatier et al., 
2009), but microfibril formation occurs in several lower organisms without fibronectin and in 
fibronectin-null cultures (Reber-Muller et al., 1995; Dallas et al., 2005), suggesting fibronectin 
acts as a facilitator rather than an essential precursor of microfibril assembly. 
Fibrillin monomers adopt a head-to-tail arrangement and form a beads-on-a-string 
appearance of microfibrils (Marson et al., 2005). However, the precise arrangement of the 
fibrillin monomers with microfibrils is a subject of intense research and debate with several, 
equally plausible working models (Baldwin et al., 2013). 
In addition to a self-assembly, a cellular involvement might also contribute to the 
microfibril formation (Kinsey et al., 2008). It has been shown that microfibril assembly requires 
fibronectin Arg-Gly-Asp (RGD)-dependent α5β1 integrins (Kinsey et al., 2008).  The interaction 
of fibrillin-1 with cells can occur through integrins α5β1, αvβ3 and αvβ6 in epithelial cells 
(Jovanovic et al., 2007; Bax et al., 2007). It remains unresolved whether the microfibril assembly 
requires direct interaction between fibrillin-1 and cells or indirect interaction through fibrillin-
binding proteins (Baldwin et al. 2013). 
The glycosaminoglycan heparan sulfate (HS), a component of syndecan and glypican 
receptors and a perlecan, is essential for fibrillin microfibril assembly as indicated by the 
inhibition of microfibril assembly by heparin supplementation (Tiedemann et al., 2001; Ritty et 
al., 2003). So far, six high affinity-binding sites between heparin and fibrillin-1 have been found 
(Tiedemann et al., 2001; Ritty et al., 2003; Cain et al., 2005). Further insights are needed to 
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determine how HS contributes to microfibril deposition. The competition between HS and 
MAGP-1 and tropoelastin to bind fibrillin-1 may regulate elastin deposition onto microfibrils 
(Cain et al., 2008). 
The first step of elastic fiber formation is the self-association of tropoelastin monomers, a 
process known as coacervation that requires thermodynamic interactions (Yeo et al., 2011). It 
has been shown that the coacervation rate depends upon the pH and temperature, salt and 
tropoelastin concentration and the presence of microfibril-associated molecules  (Cirulis et al., 
2010). Fibulin-4 and fibulin-5 delay the maturation of the tropoelastin (Choi et al., 2009). C-
terminal region of tropoelastin interact with αvβ3 (Bax et al., 2007) integrin and HS 
(Broekelmann et al., 2005). Until transfer to the microfibril platform, tropoelastin coacervate 
interacts with integrins (Bax et al., 2009) and HS (Akhtar et al., 2011; Broekelmann et al., 2005). 
This process is called microassembly. LOX or LOXL1, fibulin-4, and fibulin-5 facilitate the 
stabilization of globules by forming cross-links and help to form the insoluble elastin core, 
known as macroassembly (Yeo et al., 2011; Cirulis et al., 2010) (Figure 1.3). 
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Figure 1.3 Schematic representation of microfibril and elastic fiber assembly 
FN: fibronectin; FBN1: fibrillin-1; BMP: bone morphogenetic factor; GF:growth factor; 
FBLN4:fibulin-4; FBLN5: fibulin-5; LOX: lysyl oxidase. 
Microfibrils are formed pericellularly with the interaction of fibronectin, integrins and HSPG. 
The head-to-tail alignment of FBN monomers forms ‘beads-on-a-string’ appearance of 
microfibrils. Microassembly, coacervation of tropoelastin, is the first step of elastin assembly 
and involves the interaction of C-terminal region of tropoelastin with integrin and HSPG. After 
the deposition into the microfibril scaffold, the elastin globules are stabilized by LOX and 
LOXL1. Fibulin-4 or fibulin-5 facilitate the localization of LOX to microfibrils. This 
macroassembly forms the insoluble elastin core. 
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1.2 TGFβ SIGNALING 
1.2.1 TGFβ signaling and TGFβ receptor system 
TGFβs are a family of soluble cytokines, and they serve as multifunctional regulators in myriad 
cellular processes including cell differentiation, proliferation, recognition, apoptosis, adhesion, 
embryonic development and migration  (Santibanez et al., 2011). TGFβ also modulates ECM 
structure and composition. TGFβ has three isoforms: TGFβ1, TGFβ2, and TGFβ3, each 
synthesized as homodimeric proteins with a mass of 75 kDa (Annes et al., 2003), and cleaved by 
a furin protease to the mature TGFβ and its propeptide, also known as the latency-associated 
peptide (LAP). The LAP and TGFβ form a small latent complex (SLC) by non-covalent bonds. 
TGFβ remains inactive in this form. The LAPs form large latent complexes (LLCs) with one of 
the LTBPs (LTBP1, -3 or -4) by disulfide bonds. Most cells secrete TGFβs in LLC form. 
Consistently, LTBPs are known to facilitate the correct folding and secretion of TGFβ 
(Saharinen et al., 1999). LTBPs promote the incorporation of different TGFβs into the ECM. 
TGFβ signaling pathway alterations are found in several diseases such as cardiovascular, fibrotic, 
reproductive, wound healing disorders and cancer (Santibanez et al., 2011). 
1.2.2  Canonical TGFβ signaling pathway 
TGFβ can be activated by release from the LAP by several mechanisms, such as direct 
proteolysis, non-proteolytic dissociation by thrombospondin-1, integrins, reactive oxygen species 
or low pH (Annes et al., 2003). After activation, TGFβ binds to a TGFβ receptor in the first step 
of the signaling pathway (Wrana et al., 1994). There are three types of TGFβ receptors. Type 1 
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(TGFBR1) and type 2 (TGFBR2) receptor are the primary receptors of the canonical pathway 
and have serine/threonine kinase activity. Type 3 receptor (TGFBR3) serves as an accessory 
receptor by binding TGFβ and bringing it to the TGFBR1 and TGFBR2 (Wrana et al., 1992). 
 Binding of TGFβ to dimeric TGFBR2 that induces autophosphorylation triggers the 
signaling (Figure 1.4). This autophosphorylation recruits a homodimer of TGBFR1 and then 
forms a ligand-receptor complex. Then, TGFBR1 is activated by TGFBR2 by 
transphosphorylation (Wrana et al., 1994).  The kinase domain of the activated TGFBR1 triggers 
the downstream signaling by phosphorylation of receptor-associated SMAD proteins (R-
SMADs; SMAD 2 and 3), then undergo formation of heteromeric complexes with the co-
operating SMAD (Co-SMAD), SMAD4. After activation, SMAD complexes are translocated 
into the nucleus and serve as regulators of the transcription of target genes (Moustakas et al., 
2001). The inhibitory (I-SMAD) SMAD6 and SMAD7 compete with the R-SMADs for receptor 
or Co-SMAD binding, and thus negatively regulate TGFβ signaling (Shi and Massague, 2003). 
SMAD6 inhibits TGFβ signaling by binding to TGFBR1 and repressing the phosphorylation of 
R-SMAD proteins (Imamura et al., 1997). Another mechanism is to reduce the nuclear
translocation (Hata et al., 1998). SMAD7 conducts the inhibition of TGFβ signaling by the 
ubiquitination and degradation of TGFBR1 and TGFBR2 as a result of the release of SMURF 
proteins (Wicks et al., 2006; Ebisawa et al., 2001). 
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Figure 1.4 A schematic diagram of canonical TGFβ signaling pathway 
TGFβ binds to a TGFBR2, which recruits and phosphorylates a TGFBR1. TGFBR1 recruits and 
phosphorylates a R-SMAD (SMAD2 or SMAD3). The R-SMAD binds to a SMAD4 and forms a 
heterodimeric complex. This complex enters the nucleus and interacts with other transcription 
factors to activate and suppress target genes. 
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1.2.3 Non-canonical TGFβ signaling pathway 
Tumor necrosis factor receptor-associated factor 6 (TRAF6) associates with the TGFBR1 in a 
TGFβ dependent manner (Sorrentino et al., 2008). This complex recruits and activates TGFβ 
associated kinase 1 (TAK1) which causes an activation of p38 MAPK by phosphorylation 
(Yamashita et al., 2008; Sorrentino et al., 2008) (Figure 1.5). There are other non-canonical 
signaling pathways activated in response to TGFβ including extracellular-signal regulated kinase 
1 and 2 (ERK1/2) (Lee et al., 2007), c-Jun N-terminal kinase (JNK) (Yamashita et al., 2008; 
Sorrentino et al., 2008), and phosphoinositide 3-kinase-Akt (PI3KK-Akt) (Wilkes et al., 2005). 
Additionally, the canonical and non-canonical pathways cross-talk with each other and have 
different effects. 
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Figure 1.5 A schematic diagram of non-canonical TGFβ signaling pathway 
TAK1 is activated with the interaction of TGFBRs and TRAF6 and it leads to activation of p38 
and JNK. TGFβ also activates ERK MAPK by activation of RAS and leads to the recruitment of 
RAF and ERK through MEK1. ERK and JUN enters the nucleus and interacts with other 
transcription factors to activate and suppress target genes. 
17 
1.2.3.1 TGFβ signaling and human inherited disease 
TGFβ upregulates several genes required for the elastic fibers, including fibronectin (Ignotz et 
al.,1987), LTBPs (Ahmed et al.,1998; Weikkolainen et al., 2003), ELN (Kahari et al., 192; 
Kucich et al., 1997), LOXs  (Boak et al.,1994;Kim et al, 2008) and FBLN5 (Kuang et al., 2006). 
This regulation could be either transcriptional as in the case of fibronectin, LTBPs, LOXs, and 
FBLN5 or post-transcriptionally in the ELN and FBN1 gene. One possible mechanism how ELN 
and FBN-1 is regulated at the post-transcriptional level is through the repression of the miR29 
family by TGFβ (van Rooij et al., 2008). miR29 binding sites have been identified in many 
mRNAs of elastic fiber genes such as ELN, FBN1 and LTBP1 (Urban et al., 2014). 
Many heritable connective tissue disorders caused by mutations in ECM proteins and 
TGFβ signaling pathway components result in altered TGFβ signaling (Table 1.1). Marfan 
syndrome (MFS) is caused by the mutations in fibrillin-1, which interacts with LTBPs in the 
ECM. Increased TGFβ signaling was observed in the lung tissue of an MFS mouse model 
(Neptune et al., 2003). In these MFS mice, aortic aneurysms were also improved with an anti-
TGFβ antibody, indicating enhanced TGFβ signaling was a major factor in MFS pathogenesis 
(Habashi et al., 2006). Increased non-canonical TGFβ signaling appears to contribute to aortic 
defects in MFS mice whereas canonical TGFβ signaling is thought to be protective (Holm et al., 
2011).  
Autosomal recessive cutis laxa type 1 (ARLC1C) patients, caused by the mutations in 
LTBP4 showed increased TGFβ activity in the dermal fibroblasts (Urban et al., 2009; Dabovic et 
al.,2009). Loeys- Dietz syndrome (LDS) patients with TGFBR1 and TGFBR2 mutations also 
showed increased TGFβ signaling as well as enhanced collagen and connective tissue growth 
factor (CTGF) expression (Loeys et al., 2005). Arterial tortuosity syndrome patients with 
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SLC2A10 mutations had increased TGFβ signaling in aortic tissue samples (Coucke et al., 2006). 
Furthermore, increased TGFβ signaling was found in ADCL patients and ADCL mouse model 
with ELN mutations (Callewaert et al., 2011; Hu et al., 2010), a mouse model (Hanada et al., 
2007) and patients with fibulin-4 mutations (Renard et al., 2010), and in patients with ATP6V0A2 
mutations (Fischer et al., 2012). 
Table 1.1 Heritable disorders associated with TGFβ signaling 
Disease Mutations Clinical presentations 
Loeys-Dietz Syndrome (LDS) TGFBR1 and TGFBR2 Severe vascular effects, ocular, 
skeletal and craniofacial 
abnormalities 
Marfan Syndrome (MFS) FBN-1 Aortic aneurysms, skeletal and 
ocular abnormalities 
ADCL ELN Loose skin, aortic stenosis, 
pulmonary emphysema 
ARLC1/URDS LTBP4 Developmental delay, redundant, 
inelastic skin 
Arterial tortuosity syndrome SLC2A10 Cutis laxa with tortuous arteries 
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1.3 INHERITED DISEASES CAUSED BY ELASTIN MUTATIONS 
Elastin gene mutations result in several skin, cardiovascular and pulmonary phenotypes. 
Elastinopathies, including Williams-Beuren Syndrome (WBS), supravalvular aortic stenosis 
(SVAS), and autosomal dominant cutis laxa (ADCL) are all caused by the mutations in the ELN 
gene (Ewart et al. 1993; Olson et al.1993; Tassabehji et al., 1998) (Table 1.2). Familial SVAS 
and ADCL are caused by two distinct groups of point mutations within the elastin gene. In 
contrast, WBS is caused by the microdeletions of the region on 7q11, which includes the ELN 
gene (Ewart, 1993) and approximately 26-28 other neighboring genes (Pober et al. 2008). The 
clinical characteristics include intellectual disability, connective tissue defects, metabolic defects, 
and cardiovascular malformations, including SVAS. 
Table 1.2 Elastinopathies 
Disease Mutations Clinical presentations Molecular mechanisms 
SVAS Heterozygous loss-of-
function mutations 
Narrowing or obstruction 
of the aorta 
Haploinsufficiency 
WBS Microdeletions of the region 
on chromosome 7q11.23; 25-
28 genes including ELN 
Connective tissue and 
metabolic defects, 
cardiovascular 
abnormalities 
Haploinsufficiency 
ADCL Heterozygous frameshift 
mutations 
Loose skin, aortic stenosis, 
pulmonary emphysema 
Dominant-negative or 
toxic gain of function 
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1.3.1 Autosomal dominant cutis laxa 
Cutis laxa (CL) is a heterogeneous group of connective tissue disorders caused by the elastic 
fiber abnormalities (Berk et al., 2012). Acquired and inherited forms of cutis laxa patients show 
loose, inelastic, redundant and sagging skin. There are autosomal dominant, autosomal recessive 
and X-linked recessive inherited forms of CL and each has different clinical manifestations 
(Berk et al., 2012). Human genetic studies have identified several genes in different forms of 
cutis laxa comprising ALDH18A1, ATP6V0A2, ATP7A, EFEMPS/FBLN4, ELN, FBLN5, LTBP4, 
PYCR1 and RIN2. 
1.3.1.1 Clinical presentation 
The ADCL is mostly diagnosed during early childhood, however, it might appear in late 
childhood or early adulthood. An aged-appearance as a result of redundant and inelastic skin, 
prominent ears, long philtrum, high forehead, hoarse voice and beaked nose are the most 
important facial characteristics of ADCL patients (Berk, 2012). Clinical characteristics of ADCL 
can be mild to benign (Berk et al., 2012). However, severe systemic manifestations can be 
present including pulmonary emphysema (Rodriguez-Revenga, 2004, Urban et al., 2005), aortic 
root dilation (ARD) (Szabo et al., 2006), hernia (Szabo et al., 2006) and peripheral pulmonary 
aortic stenosis (Tassebehji et al., 1998). The pulmonary and aortic lesions can result in 
significant morbidity and mortality and to date only symptomatic treatments are available. For 
example, severe pulmonary emphysema was addressed in at least one patient with ADCL using 
lung transplantation with satisfactory results (Urban et al., 2005). Aortic root dilatation can be 
delayed by administration of beta-adrenergic blockers and rupture of aneurysms can be 
prevented by timely aortic root replacement (Szabo et al., 2006). 
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1.3.1.2 Mutational spectrum 
ADCL is mostly caused by frameshift mutations within the last five exons of the ELN gene 
which result in C-terminally elongated and secreted tropoelastin (Rodriguez-Revenga, 2004, 
Szabo et al., 2006, Tassabehji, 1998, Zhang, 1999, Hadj-Rabia, 2013; Callewaert et al., 2011). 
Unusual mutations include a heterozygous mutation in exon 25 of the elastin gene (Graul-
Neumann, 2008) and tandem duplication in the elastin gene (Urban et al., 2005). A recent de 
novo intronic mutation has been found in intron 31 of a young ADCL patient (Vodo et al., 2015). 
Approximately 30% of the ADCL patients have de novo dominant ELN mutations. Recessively 
inherited missense mutations in ELN have been described in one family with cutis laxa to date, 
suggesting heterogeneity in terms of inheritance patterns in ELN-related cutis laxa (Megarbane et 
al., 2009). Furthermore, identification of a heterozygous tandem duplication in the fibulin-5 gene 
of a cutis laxa patient raised the possibility of locus heterogeneity in ADCL (Markova et al., 
2003).   
1.3.1.3  Molecular mechanisms 
he mutations in ADCL have several cellular and biochemical effects. Alternative splicing of 
exon 32 of the ELN gene and mutation-induced exon skipping often result in several mutant 
mRNA isoforms, and this makes harder to analyze the molecular consequences of the ADCL 
mutations in exons 30-32 (Hu et al., 2010). ADCL mutations produce stable mutant mRNAs, and 
their protein products are secreted into the extracellular space (Tassabehji et al. 1998; Zhang et 
al. 1999; Rodriguez-Revenga et al. 2004; Urban et al. 2005; Szabo et al. 2006), albeit with 
reduced efficiency in some cases  (Tassabehji et al., 1998; Urban et al., 2005). The histological 
abnormalities in ADCL include a disorganized and reduced amount of elastic fibers that result in 
loss of elasticity in the connective tissue (Szabo et al., 2006). The weak fibrillin-binding capacity 
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of mutant tropoelastins leads to increased compliance and reduced stiffness of lung tissue (Hu et 
al., 2010). 
A transgenic mouse model expressing human ADCL mutant elastin was generated using 
a human elastin cDNA with a c.2114_2138del mutation in exon 30 of ELN (Hu et al., 2010).  
ADCL transgenic mouse had healthy skin and blood vessels. However, lung disease including 
airspace enlargement and severe emphysema was observed. Also, ADCL mice had enhanced 
endoplasmic reticulum stress, activation of the unfolded protein response (UPR), enhanced 
apoptosis and increased TGFβ signaling  (Hu et al., 2010). Similar findings were found in ADCL 
patient dermal fibroblasts with exon 30 mutations with longest missense peptide sequence 
(Callewaert, 2011). Lower amounts of insoluble elastin were found as a result of increased 
coacervation and elastin globule formation (Callewaert et al., 2011). The partially secreted 
mutant tropoelastin hinders the binding of tropoelastin to fibulin-5 and fibrillin-1 and results in 
changes in elastic fiber assembly such as abnormalities in elastin accumulation on microfibrils in 
ADCL cells (Sato et al., 2006).  
A human ADCL mutation (c.2012delG) in exon 30 was introduced into the human elastin 
bacterial artificial chromosome (BAC), then the mutant BAC was expressed as a transgene in 
mice with the wild-type human gene (Sugitani et al., 2012). The mutant protein was incorporated 
into elastic fibers in the skin and lung resulting in some abnormalities, however, relatively low 
levels of the mutant protein was found in the aorta suggesting tissue-specific effects on elastin 
assembly (Sugitani et al., 2012). These findings suggest different mechanisms of elastin 
assembly in aorta and lung and skin (Sugitani et al., 2012). 
Enhanced TGFβ signaling has been found in patient fibroblasts (Callewaert, 2011) and in 
a transgenic mouse model (Hu et al., 2010), however, the precise mechanisms of TGFβ signaling 
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alterations remain unclear, as does the possible contribution of these changes to the development 
of ADCL. The exact molecular mechanisms of how ELN mutations cause ADCL are still 
unknown, but dominant negative and toxic gain-of-function mechanisms have been proposed as 
molecular mechanisms for ADCL (Hu et al. 2010, Callewaert et al. 2011). 
1.3.2 Supravalvular aortic stenosis 
1.3.2.1 Clinical presentation 
SVAS occurs approximately 1 in 5,000 individuals. SVAS can occur as an isolated vascular 
disease (Eisenberg et al., 1964) or as part of the WBS with identical clinical and structural 
characteristics (Urban et al., 2001; Micale, 2010). SVAS is characterized by narrowing or 
obstruction of the ascending aorta (Eisenberg et al., 1964). Segmental narrowing of major 
arteries such as pulmonary, carotid, cerebral, renal and coronary arteries may also be part of 
SVAS (Rein et al., 1993; Kaplan et al., 1995). In children, SVAS might result in more severe 
conditions, such as myocardial infarcts and sudden death (Conway et al., 1990). Systemic 
hypertension, cerebrovascular accident, myocardial infarction and obstructive cardiomyopathy 
are the most severe and life-threatening clinical characteristics. Severe forms of SVAS may 
result in dyspnea, angina, systemic murmur and left ventricular hypertrophy. The primary 
treatment of SVAS is vascular surgery, which has an increased risk of morbidity and mortality.  
1.3.2.2 Mutational spectrum 
SVAS can be a part of WBS, a complex developmental genomic disorder, caused by 
microdeletions of the region on chromosome 7q11.23 encompassing 26-28 genes surrounding 
ELN (Ewart et al., 1993; Pober et al., 2008) or might be isolated. Several mutations consisting 
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translocations (Curran et al., 1993; von Dadelszen et al., 2000), gene deletions (Ewart et al., 
1994; Olson et al., 1995; Fryssira et al., 1997) and point mutations in the ELN (Li et al., 1997; 
Boeckel et al., 1999; Urban et al., 1999, 2000; Metcalfe et al. 2000) lead to the isolated form of 
SVAS. SVAS is inherited in an autosomal dominant manner. Most of the mutations produce 
premature termination codons and result in haploinsufficiency through nonsense-mediated decay 
(NMD) (Urban et al., 2000). If left untreated, SVAS might result in progressive heart failure and 
death. 
1.3.2.3 Molecular mechanisms 
Different types of heterozygous loss-of-function mutations in the ELN gene lead to SVAS 
(Urban et al., 2001). As a result of point mutations, translocations and partial deletions in the 
ELN gene, premature stop codons, and unstable mRNA has been observed (Metcalfe et al., 2000; 
Urban et al., 2000). Decreased levels of elastin mRNA (Urban et al., 2000, 2001) and protein 
levels as well as the reduced elastin deposition indicate that SVAS is caused by null mutations in 
ELN (Urban et al., 2002) through haploinsufficiency. 
Decreased levels of elastin in SVAS arteries leads to enhanced proliferation of vascular 
smooth muscle cells (Brooke et al., 2003). Hyperproliferation of smooth muscle cells in turn 
yields thicker, narrower arteries that lack flexibility (Baldwin et al., 2013). Similar to SVAS 
patients, heterozygous elastin knockout mice (Eln+/-) showed hypertension, enhanced lamellar 
units in all elastic arteries, enhanced number of SMC layers and decreased elastin amount similar 
to SVAS patients (Li et al., 1998). Ge et al. generated a human induced pluripotent stem cell 
(iPSC) model of SVAS to study the mechanism of the disease (Ge et al., 2012). Their model 
showed that SVAS SMCs had less organized networks of smooth muscle alpha-actin and 
increased proliferation rate than control iPSC-SMCs. Adding recombinant ELN or decreasing 
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ERK1/2 activity have been reported as promising therapy, causing inhibition of SMC 
overproliferation (Ge et al., 2012). Another potential SVAS therapy is rapamycin, an inhibitor of 
mTOR signaling, which rescues increased SMC proliferation and aortic obstruction (Li et al., 
2013). Human iPSCs model of SVAS, SVAS patients, and elastin mutant mice showed enhanced 
integrin β3 expression and activation (Misra et al., 2016). In addition, the inhibition of integrin 
β3 rescued aortic hyperproliferation and aortic stenosis, uncovering a potential therapeutic 
strategy for SVAS patients (Misra et al., 2016). 
1.3.3 Comparison of ADCL and SVAS 
SVAS and ADCL are two phenotypically different autosomal dominant inherited diseases 
caused by the mutations in the ELN gene. The clinical phenotype of ADCL includes 
predominantly abnormalities in skin and lung including aged appearance, pulmonary aortic 
stenosis, emphysema and aortic root dilatation and aneurysms. However SVAS patients have 
mostly stenoses the aorta and other elastic vessels, such as the pulmonary and coronary arteries. 
Thus, generally, ADCL predisposes to aneurysms whereas SVAS is associated with stenoses, an 
opposite vascular phenotype. However a shared vascular manifestation of both disorders is 
pulmonary artery stenosis  (Milewicz et al., 2000). 
Loss-of-function mutations including premature stop mutations, large intragenic deletions 
in SVAS lead to degradation of mRNA through NMD as a result of haploinsufficiency, whereas 
ADCL-causing mutations yield stable mRNAs and their protein products are secreted into the 
extracellular space, where the mutant protein interferes with elastic fiber assembly in a 
dominant-negative manner (Tassabehji et al. 1998; Zhang et al. 1999; Rodriguez-Revenga et al. 
2004; Urban et al. 2005; Szabo et al. 2006). In addition, mutant ADCL tropoelastin also activates 
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the unfolded protein response and apoptosis considered to be a toxic gain of function effects (Hu 
et al. 2010; Callewaert et al. 2011). ADCL is mostly caused by the mutations within the 3’ end of 
the ELN gene while SVAS mutations are broadly distributed in the ELN gene (Figure 1.6). 
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Figure 1.6 Comparison of ADCL and SVAS mutations and molecular mechanisms 
ADCL is caused by the mutations within the last 5 exons, whereas SVAS is caused by the 
mutations broadly distributed throughout the ELN gene. The disease mechanism of ADCL is 
dominant-negative and toxic gain-of-function, whereas the disease mechanism of SVAS is 
happloinsufficiency. 
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1.4 SUMMARY 
ECM and associated molecules have a myriad of roles comprising cell-cell communication, cell 
proliferation, and survival. Elastic fibers are integral parts of ECM of the connective tissues such 
as skin and large arteries. Their function is to provide elastic stretch and recoil to the connective 
tissues. The elastic fibers are assembled from fibrillin microfibrils and elastin and many 
accessory molecules facilitate the assembly process such as fibulins, LTBPs and lysyl oxidases. 
The TGFβ family of growth factors, in addition to its roles in cell differentiation, proliferation, 
apoptosis and embryonic development, has reciprocal interactions with elastic fibers. On one 
hand, through LTBPs, elastic fibers sequester and store TGFβ and permit developmentally and 
physiologically appropriate levels of growth factor activity. However, in disease states, where 
this sequestration is impaired, excess TGFβ is released and can contribute to the disease process 
as observed in Marfan syndrome. On the other hand, TGFβ serves as a major signal to enchance 
the deposition of elastic fibers, as it up-regulates the expression of all major elastic fiber 
components. Thus, TGFβ sequestration by elastic fibers serves as a negative feedback to limit 
growth factor signaling once the quality and quantity of elastic fibers is sufficient for tissue 
function.  
Structural abnormalities in elastin lead to a decrease in the integrity of elastic tissues 
including skin, lungs and large blood vessels. Therefore, elastin gene mutations lead to several 
skin, cardiovascular and pulmonary phenotypes. Microdeletions of the chromosome 7q11 
including the ELN gene lead to WBS (Ewart et al., 1993) and characterized by mental 
retardation, dysmorphic features, and arterial stenosis. Missense and premature truncation 
mutations throughout the ELN gene lead to SVAS (Curran et al., 1993). ADCL is caused by the 
frameshift mutations at the 3’ end of the elastin gene. Dominant-negative and toxic gain-of- 
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function are the most important ELN-related ADCL mechanisms and happloinsufficiency is the 
SVAS disease mechanism. However, the exact molecular mechanisms of ADCL and SVAS are 
still under investigation, especially the potential connection of these disorders to altered TGFβ 
signaling. 
1.5 SIGNIFICANCE 
1.5.1 Public Health Significance 
Rare diseases affect millions of people worldwide. Some extremely rare diseases only have an 
impact on a couple of individuals, but there are ones affect thousands or approximately 200,000 
people in USA and 1 in every 2000 in Europe. 7,000 rare diseases have been identified to date 
(Anon, 2013). The spectrum of clinical manifestations has broad diversity and heterogeneity. 
Approximately 80% of the rare diseases have genetic origin including single or multiple genes 
and chromosomal abnormalities (Boat et al., 2012). More than 200 connective tissue disorders 
have been identified to date. Individuals with a rare disease confront a wide range of challenges 
including diagnostic odyssey, lack of understanding of the natural history of diseases (what to 
expect), causes of diseases (etiology), insufficient management guidelines for physicians and 
lack of treatment. Understanding the disease etiology and molecular and physiological 
mechanisms can improve diagnosis and the development of molecularly targeted treatments, 
such as enzyme replacement therapy for lysosomal storage diseases, channel potentiators for 
cystic fibrosis and and exon skipping therapy for Duchenne muscular dystrophy. 
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The genetic profile of ADCL and SVAS are known, but the genotype and phenotype 
spectrum is incomplete, and the genotype-phenotype correlations are unclear. Some molecular 
mechanisms are emerging, however the full impact of these mechanisms on disease development 
is not understood. My study will improve the understanding of the molecular mechanisms of 
ADCL and SVAS. 
1.5.2 Basic scientific significance 
ECM and associated proteins have many mechanical, chemical and biological functions such as 
cell-cell communication, cell proliferation, migration, cell differentiation, development, and 
survival. ECM molecules bind and regulate several growth factors such as TGFβ. TGFβ families 
have roles in cell proliferation, cell growth, inflammation, apoptosis and extracellular matrix 
production (Santibanez et al., 2011). Defects in TGFβ lead to many pathological conditions such 
as fibrosis, autoimmune disease and tumor cell growth (Santibanez et al., 2011). Previous studies 
showed that there is an increased TGFβ signaling in ADCL patients (Callewaert et al., 2011; Hu 
et al., 2010), but the exact molecular mechanism of the disease still unknown. In this study, we 
will look for the possible mechanisms of ADCL and TGFβ signaling leading to pathogenesis of 
the disease and the effects of ELN mutations in elastic fibers. Our findings will establish new 
connections between elastin biosynthesis and growth factor signaling and shed light to the 
contribution of allelic imbalance to the molecular disease mechanisms in ADCL. In addition, 
genetic and functional analysis of SVAS will contribute to the molecular mechanisms of 
elastinopathies. 
Uncovering the nature of connections between elastin and growth factor signaling may 
help developing treatments for cutis laxa that restores correct growth factor regulation and 
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improve elastic fiber function. In addition, molecular insights into rare diseases might be relevant 
to common, complex diseases characterized by elastin degradation including aneurysms, chronic 
obstructive pulmonary disease and emphysema (Robinson et al., 2006; Shifren and Mecham, 
2006). 
1.6 HYPOTHESIS AND SPECIFIC AIMS 
1.6.1 ADCL 
ADCL is caused by the mutations in ELN the gene and characterized by the loose, redundant and 
inelastic skin, pulmonary emphysema, aortic root dilation (ARD), hernia and peripheral 
pulmonary aortic stenosis. My major goal was to identify the molecular and cellular mechanisms 
caused by which defects in ELN gene and its product contribute to the pathogenesis of ADCL. I 
hypothesized that ELN mutations in ADCL patients result in enhanced TGFβ signaling 
contributing to the pathology of ADCL. 
Aim 1. Analyze the cellular consequences of ELN mutations and investigate the molecular 
mechanism of signaling by the TGFβ pathway in ELN mutant cells. 
Human dermal fibroblasts from ADCL patients with exon 30 or exon 34 mutations in the ELN 
gene and age and sex-matched controls were used to study the alterations in intracellular TGFβ 
signaling and extracellular TGFβ activity. The expression and activation of TGFβ receptors 
(TGFBRs) and TGFβ pathway components and target genes were also studied to identify the 
possible mechanisms of altered TGFβ signaling. Allelic expression of wild-type and mutant 
alleles and elastin deposition were also analyzed. 
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Aim 2.  Manipulate TGFβ signaling and evaluate the assembly of elastic fibers by wild-type 
and mutant cells. 
TGFβ signaling was manipulated to understand the output of the TGFβ signaling pathway in 
ELN-mutant and control cells. TGFβ was administered to ADCL patient and control cells for ten 
days, and allelic expression, and elastin assay experiments were performed. This aim helped me 
determine if TGFβ signaling contributes to the disease, ameliorates it or simply a marker of the 
disease. 
1.6.2 SVAS 
SVAS is also caused by the mutations in the ELN gene and characterized by narrowing or 
obstruction of the ascending aorta. I studied an SVAS family segregating an 80 kb duplication 
which includes 5’-flanking sequences, exon 1 and intron 1 of the ELN gene.  My primary goal is 
to solve the exact nature of this duplication and how it may lead to the gene dysfunction. In 
addition, my studies might shed light into the mutational spectrum of SVAS. 
Aim 1. Genetic and functional analysis of SVAS family with a duplication of the ELN gene 
Dermal fibroblasts from an SVAS family with an 80 kb duplication were used to solve the exact 
nature of the duplication. Expression analysis of the duplication was performed, and elastin 
levels were measured in SVAS cells. 
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2.0  MATERIALS AND METHODS 
2.1.1 Cell culture conditions 
Dermal fibroblast cells were cultured from control individuals and ADCL and SVAS patients 
and were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS), 1% antibiotic-antimycotic (ABAM), 20 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) and 45 mM sodium bicarbonate (NaHCO3).  All dermal 
fibroblast cells were incubated at 37 °C, 5% CO2 in a humid atmosphere, and used at passages 3-
6 for ADCL patient and control fibroblasts and 4-6 for SVAS patient and control fibroblasts. The 
media was exchanged every 48 hours, and the cells were subcultured using 0.05%-0.25% 
trypsin/ethylenediaminetetraacetic acid (EDTA) solution. As a part of regular quality control 
procedure, cells were tested for mycoplasma by PCR (Table S1). 
2.1.2 DNA isolation 
Genomic DNA was extracted from dermal fibroblast cultures using the Gentra PurGene Cell Kit 
(Qiagen, USA). Briefly, the cells were trypsinized and resuspended in 3 mL Cell Lysis Solution. 
15μL RNase A Solution was added, and the sample was incubated at 37°C for 5 min followed by 
3 min incubation on ice. 
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One mL Protein Precipitation Solution was added, and the mixture was centrifuged at 
2000xg for 10 min. After adding 3mL Isopropanol, the solution was centrifuged at 2000xg for 3 
min. The DNA pellet was washed with 3 mL 70% ethanol, centrifuged at 2000xg for 1 min and 
air-dried for 10 min. The cell pellet was dissolved in 400 μL DNA Hydration Solution. DNA 
concentration was measured by UV spectrophotometry, and the concentration was set to 200 
ng/μL in all samples. The DNA was stored at -20°C. 
Identity test was performed with genomic DNA of all SVAS samples using AmpFlSTR 
Identifier PCR Amplification Kit using GS500LIZ standard (Applied Biosystems) (Table S2). 
2.1.3 RNA purification 
Total RNA was extracted from fibroblast cultures using TRIzol reagent (Invitrogen) according to 
the manufacturer’s protocol for large-scale extraction. For homogenization, 1 mL TRIzol reagent 
was added per 10 cm2 cell culture dish surface area after washing with PBS and for complete 
lysis, cells were pipetted up and down many times. 0.1 mL BCP per 1 mL TRIzol reagent was 
added and after 2-3 min incubation at room temperature, the sample was centrifuged at 12,000xg 
for 15 min at 4°C. This step separates the sample into a clear top layer with RNA, an interface 
and a red bottom organic layer with DNA and proteins. The top clear phase was placed into a 
new tube, and 0.5 mL of 100% isopropanol per 1mL TRIzol reagent was added for RNA 
precipitation. After 10 min incubation at room temperature, the sample was centrifuged at 
12,000xg for 10 min and a gel-like RNA pellet was formed. The RNA pellet was washed with 1 
mL 75% ethanol and the sample was centrifuged at 7500xg for 5 min. The pellet was air-dried 5-
10 min and was resuspended in 100 μL diethyl-pyrocarbonate (DEPC)-treated water.  
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RNase-free DNase (Qiagen) treatment was performed to remove DNA from RNA 
samples before RT-PCR. Briefly, 2.5 μL DNase I stock solution, RNA, and Buffer RDD were 
mixed and incubated at room temperature (20-25 °C) and the RNA was purified using RNeasy 
mini kit (Qiagen). RNA concentration was measured by UV spectrophotometry, and the 
concentration was set to 200 ng/μL. 
For small-scale RNA extraction from 6-well plates, RNeasy Mini Kit (Qiagen) was used. 
350μL Buffer RLT was added to lyse the cells. Homogenization was performed by pipetting up 
and down the solution several times and by vortexing for 1 min. To remove the DNA, on-column 
DNase digestion was performed during RNA purification. After several buffer washes and 
centrifugation steps, the RNA was eluted in 50μl RNase-free water. RNA concentration was 
measured by UV spectrophotometry and the concentration was set to 200 ng/μL. 
2.1.4 Reverse transcription polymerase chain reaction 
cDNA was synthesized from 1 μg total RNA using Superscript III Reverse Transcriptase kit 
(Invitrogen). First, 1 μL of random hexamers (50ng/μL), 1 μL of dNTPs and the template RNA 
and DEPC-treated water (up to 10μL) were mixed and the mixture was incubated at 65ºC for 5 
min and then placed on ice at least 1 min. cDNA Synthesis Mix was prepared including 2μL 
10XRT Buffer, 4μL 25 mM MgCl2, 2μL 0.1 M DTT, 1μL RNaseOUTTM (40 U/μl) and 1μL 
SuperScript III RT (200 U/μL) and added to each RNA/primer mixture and incubated at 25ºC for 
10 min, 50ºC for 50 min and 85ºC for 5 min. After chilling the reaction tubes on ice, 1μL RNase 
H was added to each tube and incubated at 37ºC for 20 min. The final cDNA was either stored at 
-20ºC or used for further studies immediately. No template and no RT controls were included as
quality controls for SVAS RT reactions used for the analysis of pre-mRNA (Figure 4.4). 
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2.1.5 Polymerase chain reaction (PCR) 
Genotyping was performed to look for heterozygous individuals for allele-specific gene 
expression studies (SVAS family). 9 SNPs were tested (rs884843, rs868005, rs2071307, 
rs28763986, rs17855988, rs41500150, rs20062910, rs4556939 and rs4717865) (Table S1). PCR 
was performed using the Qiagen Multiplex PCR Kit with primers specific to each SNP 
(Supplementary Table S3). The PCR products were visualized using agarose gel electrophoresis 
in gels containing 0.35 μg/mL ethidium bromide (Fisher). 
2.1.6 DNA fragment analysis 
The first-strand cDNA was amplified using fluorescently labeled primers in ADCL patients. The 
primers used in PCRs are shown in Table 2.1. PCR was performed with the tailed primer (M13-
hELNe29-1s) and hELNe34-1a for 10 cycles.  A second PCR reaction was performed with 1 μL 
of previous PCR product using the M13-FAM and hELNe34-1a primers for 15 cycles. 1:10 
dilutions of fragments were run with a GeneScan 500 LIZ size standard (Applied Biosystems) on 
an Applied Biosystems 3730 genetic analyzer (Applied Biosystems). The data were processed 
using Peak Scanner software (Applied Biosystems) (Table 2.1, Figure 2.1). To determine the 
exponential range of the PCR, different cycles ranging from 20-40 were used in pilot 
experiments and cycle numbers 28-30 were determined to be within the exponential range; 
therefore, cycle number 30 was used in subsequent experiments. Another pilot experiment was 
performed to see whether TGFβ treatment affects the allelic expression of wild- type and mutant 
alleles using 5 different time points including 1-day, 2-day, 4-day, 10-day and 15-day. 
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Table 2.1 Primers used in ADCL fragment analysis 
 
Name of primers Primer sequence (5’3’) Tm  
M13-hELNe29-1s /5-M13/AGCCAAAGCTGCTGCCAAAG 68.9 
hELNe34-1a CATGGGATGGGGTTACAAAG 58.5 
M13-FAM /56-FAM/GCTCACGACGTTGTTAAACGAC 56.6 
hELNe29-1s AGCCAAAGCTGCTGCCAAAG 59.2 
 
 
Genotyping for a tetranucleotide repeat in intron 1 (Urban et al., 1997) was performed on 
genomic DNA (gDNA) and cDNA from fibroblasts of each indicated individual using 
fluorescently labeled primers shown in Table 2.2. First PCR reaction was performed with 
hELNi1.11s and hELNi1.11a primers for 20 cycles. A second PCR reaction was performed with 
5’-FAM-hELNi1.3s and hELNi3.1a for 30 cycles. 
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Table 2.2 Primers used in SVAS fragment analysis 
Name of primers Primers sequence (5’3’) Tm 
hELNi1.11s GAGAAAAGTAAATGGGGCCA 52.8 
hELNi1.11a AATCACCACCTCCAAATGCT 54.6 
5’-FAM-hELNi1.3s /56-FAM/GCCCACATGGGCAGATTGCT 61 
hELNi3.1a CCCTCATCCACAGACAGGTC 57.2 
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Figure 2.1 DNA fragment analysis experiment 
RNA was extracted from dermal fibroblasts and cDNA was synthesized. PCR was performed 
using tailed and fluorescently-labeled primers, fragments were run with a GeneScan 500 LIZ 
standard on ABI3730 genetic analyzer. 
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2.1.7 Quantitative PCR 
Q-PCR was performed to determine the expression of ELN, TGFBR1, TGFBR2, CTGF, PAI1, 
TGFB1, SMAD6 and SMAD7 in ADCL patients and control individuals. Real-time PCR was 
performed using the QuantStudio 12K Flex Real-Time PCR System (ThermoFisher Scientific). 
An inventoried TaqMan ® Gene Expression Assay (Applied Biosystems) was used for each gene. 
The reaction mix was prepared including 4.5μL cDNA, 5μL Taqman Universal Master Mix II, 
with UNG and 0.5μL 20x FAM dye-labeled TaqMan Gene Expression Assay. The reagents were 
pipetted into a 384-well plate. The plate was briefly centrifuged before running under the 
following conditions (Table 2.3). 
Each sample was run with 3 biological and 4 technical replicates and Ct measurements 
for each sample were normalized to a housekeeping control gene, GAPDH. The comparative Ct 
method (2 -ΔΔCt ) was used to determine the relative expression of the previously described genes 
in ELN-mutant and control human dermal fibroblasts. 
Table 2.3 Q-PCR conditions 
UNG 
Incubation 
Polymerase 
Activation 
Denaturation Annealing/Extension 
Temperature 
(ºC) 
50 95 95 60 
Time 2 min 10 min 15 sec 1 min 
Cycles 1 1 40
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2.1.8 Topo TA cloning 
To identify the mutant ELN mRNA transcripts of patients with mutations in exon 34 (c.2236-
7C>A), cDNA samples were prepared from dermal fibroblast cultures using the Superscript III 
Reverse Transcriptase kit (Invitrogen) as described above. PCR was performed using primers 
complementary to exon 29 (hELNe29-1s) and exon 34 (hELNe34-1a) (Table 2.1). PCR products 
were cloned into a TOPO TA vector (Invitrogen) and transformed using TOP10 competent 
Escherichia coli (E-coli) cells (Invitrogen) according to the manufacturer’s instructions 
(Invitrogen). The colonies were selected and grown overnight in LB broth containing 50 μg/mL 
ampicillin. Plasmid DNA was isolated using the Qiaprep Spin Miniprep Kit (Qiagen). 
2.1.9 DNA sequencing 
Plasmid DNA (100 ng/μL) was mixed with 4 μL water and 3 μL of the primer (0.8 μM). 10 μl of 
PCR product was treated with 1μl exonuclease I, shrimp alkaline phosphatase (ExoSAP-IT, 
Thermo Fisher) and incubated 37°C for 40min to remove unincorporated primers and dNTPs, 
followed by 15 min at 80°C to inactivate the enzymes. The treated PCR product (4 μL) was 
mixed with 3.5 μL water and 3 μL primer (0.8 μM). Plasmid DNA or PCR product mixtures 
were sent for sequencing to Eurofins MWG Operon. The sequences were analyzed using the 
Sequencher v5.2.4 software. 
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2.1.10 Fastin elastin assay 
The colorimetric Fastin Elastin Assay (Biocolor) was carried out in accordance with the 
manufacturer’s instructions to quantify the amount of soluble elastin. Between 5 μg and 70 μg 
elastin could be measured with this assay. Human dermal fibroblasts were harvested 1 week after 
confluence from 60 mm dishes by scraping and insoluble elastin was converted to a soluble form 
by incubating the cell suspensions at 100 °C in 0.25M oxalic acid for 1 hour. α-elastin standards 
(0, 12.5, 25.0 and 50.0 μL) were prepared. The extract and the α-elastin standards were treated 
with Elastin Precipitating Reagent and the tubes were centrifuged at 10,000 g for 10 minutes. 
One mL of dye reagent was added into each tube. After a 90-minute incubation, the tubes were 
centrifuged at 10,000 g for 10 minutes and unbound dye was drained off. Dye Dissociation 
Reagent (250 μL) was added to each tube, and the samples were then transferred to a transparent 
96-well plate to measure the absorbance at 513 nm, using GeNIOS plate reader (Tecan) (Figure
2.2). 
A pilot Fastin elastin assay was also performed to see if TGFβ treatment affects elastin 
deposition in ADCL and control dermal fibroblasts. TGFβ was administered in cells cultured in 
60 mm dishes in 5 different time points including 1, 2, 4, 10, and 15 days. Parallel cell cultures 
for each time point were used and the elastin concentration was normalized by cell numbers. The 
number of cells were counted by Cellometer Mini Cell Counter (Nexcelom). Based on the results 
of this pilot experiment, a 10-day TGFβ treatment was performed, and elastin levels were 
quantified. 
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Figure 2.2 Fastin elastin assay 
Elastin is extracted from dermal fibroblasts and the sample is heated at 100 C to extract the 
elastin as alpha elastin. Following the precipitation of elastin with the Elastin Precipitating 
Reagent, an elastin-dye complex was formed by adding the Dye Reagent. To release the elastin 
bound dye, Dye Dissociation Reagent was added and elastin concentration was measured at 513 
nm. 
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2.1.11 Protein extraction 
To study intracellular pathways, cell lysates were collected from dermal fibroblasts using lysis 
buffer (CelLyticTM M, Sigma) with Protease and Phosphatase Inhibitors (1:100) (Sigma). Briefly, 
the plates were incubated with 500 μL lysis buffer per 10 cm plate 40 min at 4°C on a shaker and 
were detached from the plates by scraping with chilled cell scrapers. Glass homogenizers were 
used to complete the cell lysis and the samples were centrifuged for 20 min, at 13200 rpm, at 
4°C. 
The Mem-PERTM Plus Membrane Protein Extraction Kit (Thermo Scientific) with 
Protease and Phosphatase Inhibitors (1:100) was used to collect membrane proteins. Adherent, 
dermal fibroblasts were washed with the Cell Wash Solution twice in 10 cm plates and were 
scraped in 3 mL Cell Wash Solution After the cell pellet was centrifuged at 300xg for 5 min, cell 
pellets were resuspended in 500 μL Cell Permeabilization Buffer by vortexing and incubated 10 
min at 4°C with intermittent mixing. Following a 15-minute centrifugation at 16000xg, the 
pellets containing membrane proteins were resuspended in 250 μL Solubilization Buffer and 
incubated at 4°C for 30 min with intermittent mixing. The mixture was centrifuged at 16000xg 
for 15 min at 4°C and the supernatant containing the membrane proteins were collected.  
To calculate the protein concentration, a Bradford assay (Zor T., et al. 1996) was 
performed. Briefly, a standard curve was prepared diluting the albumin standards (1000 μg/mL, 
100 μg/mL and 10 μg/mL) and the absorbance was measured at a wavelength of 595 nm and the 
cell lysate or membrane protein concentrations were determined using the standard curve. 
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2.1.12 Immunoblotting 
For the baseline conditions, cells were left in serum-free or serum-containing (10% FBS) media 
overnight, and cell lysates were collected. TGFβ1 (PeproTech, Rocky Hill, NJ) and TGFBR1 
inhibitor (LY364947; Calbiochem) were prepared in tissue culture medium at concentrations of 5 
ng/mL and 25 μM, respectively, and cells were treated for 90 minutes.  
Proteins were separated by size by sodium dodecylsulfate polyacrylamide gel 
electrophoresis (SDS-PAGE). The samples were mixed with Laemmli Sample Buffer (2X, Bio-
Rad) with 1% β-mercaptoethanol or Lithium Dodecyl Sulfate (LDS) Sample Loading Buffer 
(4X, Thermo Scientific Pierce). The cell lysates were denatured at 95°C for 5 min and the 
membrane proteins were incubated at room temperature for 30 min. The samples and protein size 
markers were loaded on the gel, and subjected to electrophoresis at 90V for 90 min. After 
electrophoresis, the proteins were transferred to a polyvinylidine fluoride (PVDF) membrane at 
80V for 120 min in a Bio-Rad Mini Trans-Blot® Electrophoretic Transfer Cell. When the 
transfer was finished, the PVDF membranes were removed, washed in PBST (1x PBS, 0.1% 
Tween-20) and non-specific binding sites were blocked in blocking buffer (PBS with 0.1% 
Tween 20 containing 5% non-fat milk powder) at 4°C overnight or 2 hours at room temperature. 
To detect the proteins of interest, the membranes were incubated at 4°C overnight with the 
primary antibody (Table 2.4). Membranes were washed 5 times for 10 min in PBST (1xPBS-
0.1% Tween 20) and incubated with secondary antibodies for 1 hour at room temperature (Table 
2.4). After final washes with PBST (5X for 10 min), immunoreactive signals were detected with 
SuperSignalWest Pico Chemiluminescent Substrate (Thermo Scientific), SuperSignal West 
Femto Maximum Sensitivity Substrate (Thermo Scientific) or Luminata Forte Western HRP 
Substrate (Millipore). 
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Table 2.4 Antibodies for immunoblotting 
Antibody Species Dilution Manufacturer/Cat.No. 
Primary pSMAD2 Rabbit polyclonal 1:1000 Cell Signaling; 3101 
pERK Rabbit polyclonal 1:1000 Cell Signaling; 197G2 
pSMAD3 Rabbit polyclonal 1:1000 Cell Signaling; 9520 
pJNK1 Rabbit polyclonal 1:1000 Cell Signaling; 4668 
pP38 Rabbit polyclonal 1:1000 Cell Signaling; 9211 
pTGFBR1 Rabbit polyclonal 1:500 Abcam; ab112095 
TGFBR1 Rabbit polyclonal 1:1000 Cell Signaling; 3712 
TGFBR2 Rabbit polyclonal 1:500 Sigma; SAB4502958 
TGFBR3 Rabbit polyclonal 1:1000 Cell Signaling; 2519 
Tubulin Mouse monoclonal 1:1000 Sigma; T8203 
Secondary Anti-rabbit Goat polyclonal 1:10,000 Thermo; PAI-20391 
Anti-mouse Goat polyclonal 1:10,000 Jackson & Immunology 
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2.1.13  TGFβ activity assay 
Cultured mink lung epithelial cells (MLECs) stably transfected with a plasmid construct with a 
TGFβ-responsive plasminogen activator inhibitor-1 promoter connected to a luciferase cDNA 
(Abe et al., 1994) were used as reporter cells to measure the activity of TGFβ. MLECs grown in 
DMEM with 2% FBS were plated in 96-well plate (2x105 cells/mL) and incubated 6 hours.      
 Conditioned medium was collected and used untreated to measure active TGFβ and an 
aliquot was heat-activated (10 min at 100°C) to measure total TGFβ levels. A standard curve was 
generated with decreasing concentrations of TGFβ1 (PeproTech) starting from 2000 pg/mL. The 
media from MLECs were removed and replaced with different concentrations of TGFβ1, 
conditioned media samples and heat-activated media samples and the plate was incubated 
overnight at 37°C. The media were aspirated, the cells layer were washed with PBS, and were 
lysed using the Reporter Lysis Buffer (Promega). The luciferase activity was measured in a plate 
reader as relative light units (RLU). RLU values were converted to TGFβ activity using the 
TGFβ standard curve. 
2.1.14 Statistics 
Means and standard errors of means (s.e.m) were calculated, and either paired or unpaired, two-
tailed student’s t-tests were used to compare means, as specified in the figure legends. The 
number of replicates for each experiment is also shown in the figure legends. GraphPad Prism 6 
software was used for statistical tests. Results with p values < 0.05 were considered to be 
statistically significant. 
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3.0  MOLECULAR CONSEQUENCES OF ELASTIN GENE MUTATIONS IN 
AUTOSOMAL DOMINANT CUTIS LAXA 
3.1 RESULTS 
3.1.1 Mutations 
Dermal fibroblasts from ADCL patients with ELN mutations in exon 30 and exon 34 were 
selected, with 4 cell lines each (Figure 3.1, Table 3.1). The predicted protein products of 
mutations in exon 30 and exon 34 gene are shown in Figure 3.2. A matching control fibroblast 
line was selected for each ADCL cell line. ADCL/control pairs were perfectly matched for 
passage, and 63% matched by sex. The maximum age difference between cases and controls was 
9 years. The mean age difference was 1 years and the difference was not significant statistically 
(t-test). 
The identities of the mutant mRNA products in the cells with c.2336-7C>A mutation in 
exon 34 were determined by cloning RT-PCR products and sequencing them. We found that 
there was a TCCAG insertion between exon 33 and exon 34 as a result of the activation of a 
cryptic splice site (c.2335_2336insTCCAG). All ADCL cell lines had frameshift mutations 
except one with a missense mutation in exon 34 (p.G779D). Two cell lines (7009 and 7002) were 
from patients published previously (Szabo et al., 2006). Mutation p.G779D has been reported 
previously (Hu et al., 2006 and Kelleher et al., 2005) in other patients. The mutations of in 
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patients 7157, 7159, 7078, 7304 and 7164 are first reported here. The mean ages for patients with 
mutations in exon 30 and 34 were 16 and 26.5 years, respectively, but the difference was not 
significant statistically (t-test). The passage numbers were also not significantly different 
between the 2 ADCL groups. Chi-square test was performed to see if the sex is different between 
patients with exon 30 mutations and patients with exon 34 mutations and found that there was 
not a statistically significant difference in sex between 2 ADCL groups. 
 
 
 
 
 
 
 
 
 
Figure 3.1 Schematic representation of the 3’-end of ELN with the location of the mutations 
identified in each patient  
The patient identification numbers are shown in red and the corresponding mutations are in 
black. 
 
 
 
 
 
 
 
 
 
50 
Figure 3.2 Predicted protein products of ADCL mutations located in exon 30 and exon 34 
compared to wild-type (WT) tropoelastin 
Purple rectangles: hydrophobic domains, orange ovals: crosslinking domains, yellow rectangle: 
signal peptide, yellow oval: C-terminal domain, red: domains translated in reading frame 3. A: 
protein products of ADCL mutations located in exon 30. Note that when exon 32 is retained, it 
contains a premature termination codon in this frame (MT e32 in). However, when exon 32 is 
skipped as a result of an alternative splicing event, which occurs in 75% of the transcripts, 
reading frame 3 extends past the normal termination codon found in reading frame 1 (MT e32 
out). B: protein products of ADCL mutations located in exon 34. 
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Table 3.1 ELN mutations in subjects 
ID Exons cDNA Genomic Protein 
7009 30 c.2132_2156del g.35443_35466del p.G711fs*36,p.G711fs*82
7157 30 c.2137delG g.35448delG p.A713fs*42,p.A713fs*88
7002 30 c.2177delC g.35488delC p.P726fs*29, p.P726fs*75
7159 30 c.2177delC g.35488delC p.P726fs*29, p.P726fs*75
7078 34 c.2336-7C>A g.40463C>A p.G779Vfs*42
7304 34 c.2336-7C>A g.40,463C>A p.G779Vfs*42
7164 34 c.2336-7C>A g.40463C>A p.G779Vfs*42
7052 34 c.2336G>A g.40470G>A p.G779D
cDNA and protein numbering are based on transcript ENST00000358929. In addition, exon 30 
mutation names at the protein level are also shown based on ENST00000358929 with exon 32 
deleted to reflect common alternative splicing of this exon. 
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Table 3.2 ELN mutant and control cells used in the study 
ID Age (years) Sex Passage 
Number 
7009 12 Male P5 
9215 (CRL-2211) 9 Female P5 
7157 6 Female P5 
9175 12 Female P5 
7002 2 Female P6 
9214 (CRL-1509) 0 Male P6 
7159 44 Female P4 
9173 35 Female P4 
7078 30 Male P5 
9001 31 Male P5 
7304 40 Male P3 
9001B 37 Male P3 
7164 23 Male P4 
9063 26 Female P4 
7052 13 Female P5 
9175 12 Female P5 
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3.1.2 Increased expression of the mutant allele in ADCL 
To evaluate the consequences of ADCL mutations, I checked first whether the mutations in exon 
30 and exon 34 affect the overall ELN expression levels. Quantitative RT-PCR showed a 
decreased ELN mRNA expression in patients with exon 30 mutations and an increased ELN 
mRNA expression in patients with exon 34 mutations compared to controls (Figure 3.3A). 
However, with the two patient groups combined, no significant difference was found in the total 
ELN mRNA expression of ADCL cells compared to controls (Figure 3.3B).  
Because the expression of the mutant allele relative to wild type allele could influence the 
severity of the disease, I sought to analyze allelic expression in the samples. Consistent with 
previous studies showing increased abundance of mutant mRNA in ADCL patients (Callewaert 
et al., 2011), I found higher levels of mutant mRNA in all patients except a patient with a 
c.2177delC mutation where the increase in the expression of the mutant allele did not reach
statistical significance (Figure 3.4). In one patient (7052), I could not differentiate between WT 
and MT alleles, because she had a missense mutation in exon 34 (c.2336G>A), thus the mutant 
product could not be distinguished from the normal by size (data not shown). The allele sizes for 
each patient either with exon 30 or exon 34 mutations are shown in Table 3.3. 
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Figure 3.3 ELN mRNA levels among patients and controls  
A: Quantitative RT-PCR shows a decreased ELN mRNA expression in exon 30 patients and 
increased ELN mRNA expression in exon 34 patients. B: No significant difference was found in 
ELN mRNA levels by combining exon 30 and exon 34 patients and controls. Data are means ± 
s.e.m of 3 biological replicates and 4 technical replicates were used in each individual. The
reference gene was GAPDH. Unpaired t-tests were used to compare the expression levels of
controls and patients with p values shown above each graph. This experiment was performed
once. C: controls, P: patients.
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Figure 3.4 Semiquantitative fragment analysis of mRNA products of wild type and mutant 
alleles  
A-G: Increased relative expression of mutant and wild type alleles in patients with mutations in
patients with exon 30 and 34 mutations in ELN gene. A-D: patients with exon 30 mutations, E-G:
patients with exon 34 mutations.Wild-type and mutant transcripts were studied in each indicated
individual using fluorescently labeled primers. The products were sized and quantified using a
genetic analyzer and the Peak Scanner software. Allele intensities were normalized to average
wild type (WT) allele signals in each sample. Data are means ± s.e.m of 3 biological replicates
and 3 technical replicates in each individual. WT allele intensity was compared to mutant (MT)
allele intensity using unpaired 2-tailed t-tests with the p-values shown above each graph. This
experiment was performed twice with similar results.
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Table 3.3 Allele sizes for each ADCL sample based on fragment analysis 
Sample Full Length WT Full length MT WT-e32 MT-e32 
7009 398 bp 374 bp 345 bp 321 bp 
7157 398 bp 397 bp 345 bp 344 bp 
7002 398 bp 397 bp 345 bp 344 bp 
7159 398 bp 397 bp 345 bp 344 bp 
7078 398 bp 403 bp 345 bp 350 bp 
7304 398 bp 403 bp 345 bp 350 bp 
7164 398 bp 403 bp 345 bp 350 bp 
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3.1.3 Reduced elastin deposition in ADCL 
Previous studies showed approximately 25-35% reduction in the levels of elastin in ADCL 
patients compared to control cells (Callewaert et al., 2011).  Fastin elastin assay detected 
significantly lower amounts of elastin (33% reduction in patients with exon 30 mutations and 
24% reduction in patients with exon 34 mutations) in our ADCL cells compared to controls, 
confirming elastin deposition is impaired in our samples (Figure 3.5). 
Figure 3.5 Reduced elastin deposition in patients with exon 30 and exon 34 mutations 
Fastin elastin assay was performed to measure the elastin from ADCL and matched control 
fibroblasts. Data are means ± s.e.m of 3 biological and 3 technical replicates in each individual. * 
P<0.05 using the unpaired student’s t-test. C: controls; P: patients. This experiment was 
performed twice with similar results. 
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3.1.4 Increased canonical TGFβ signaling in ADCL patients with exon 30 mutations 
In previous studies, increased TGFβ signaling, as measured by increased levels of SMAD2 
phosphorylation was observed in ADCL patients with ELN mutations (Callewaert et al., 2011). 
To understand the molecular mechanisms of these changes and Eln is intermittently involved in 
TGFβ signaling, I studied canonical (SMAD-dependent) and non-canonical (SMAD-
independent) pathways in ADCL samples. Protein lysates from patients with exon 30 and exon 
34 patients and age and sex matched controls were used and immunoblotting was performed 
using pSMAD2 and pSMAD3. In patients with exon 30 mutations, SMAD2 phosphorylation was 
increased under serum and serum-free baseline conditions (Figure 3.6A and B) and remained 
increased upon TGFβ supplementation (Figure 3.6C). TGFBR1 inhibitor treatment abolished the 
difference in SMAD2 phosphorylation between patients and controls (Figure 3.6D). No 
significant difference was found in pSMAD3 levels under the 10% serum condition (Figure 
3.6A), but SMAD3 phosphorylation was increased under the serum-free condition (Figure 3.6B) 
and remained increased upon TGFβ supplementation (Figure 3.6C). TGFBR1 inhibitor treatment 
abolished the difference in SMAD3 phosphorylation between patients and controls (Figure 3.6 
D). 
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Figure 3.6 Increased canonical TGFβ signaling in patients with exon 30 mutations 
Immunoblotting of protein extracts from dermal fibroblasts under the following conditions: A-B: 
untreated (10% serum and serum-free), C: TGFβ1 stimulation for 90 min or D: TGFβ1 and 
TGFBR1 inhibitor for 90 min in patients with exon 30 mutations. Immunoblots were quantified 
by densitometry. pSMAD2: phosphorylated SMAD2; pSMAD3: phosphorylated SMAD3, NS: 
non-significant. Bar graphs show the mean ± s.e.m. * P<0.05: obtained from t-test. C: controls 
(n=4); P: patients (n=4). This experiment was performed once. 
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To investigate whether increased TGFβ signaling is a shared mechanism in ELN-related 
cutis laxa, I analyzed the 4 patients with exon 34 mutations and 4 control dermal fibroblasts. No 
significant difference was observed in the levels of pSMAD2 and pERK levels between patient 
and controls under any treatment conditions (Figure 3.7). 
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Figure 3.7 Normal TGFβ signaling in patients with exon 34 mutations 
 Immunoblotting of protein extracts from dermal fibroblasts under the following conditions: A-
B: untreated (10% serum and serum-free), C: TGFβ1 stimulation for 90 min or D: TGFβ1 and 
TGFBR1 inhibitor for 90 min in patients with exon 34 mutations. Immunoblots were quantified 
by densitometry. pSMAD2: phosphorylated SMAD2; NS: non-significant. Bar graphs show the 
mean ± s.e.m. * P<0.05: obtained from t-test. C: controls (n=4); P: patients (n=4). This 
experiment was performed once. 
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3.1.5 TGFβ activity in exon 30 mutant cells 
As we found an increased canonical TGFβ signaling in ADCL, we wanted to test if this was 
related to any alterations in the levels of extracellular TGFβ. Conditioned media samples were 
collected from 4 mutant and 4 control fibroblast cell lines to measure active and total TGFβ 
levels. TGFβ reporter cells (Abe et al., 1994) were used for activity measurements. To assay for 
total TGFβ, samples were heated (100°C, 10 min) to activate latent TGFβ prior to adding them to 
MLECs. Neither active nor total forms of TGFβ showed any significant difference between 
mutant and control cells (Figure 3.8), although there was a trend towards lower activity in 
patients. Therefore, increased intracellular TGFβ activity in patient cells was not explained by 
commensurate changes in extracellular growth factor activity. 
Figure 3.8 TGFβ activity in conditioned media of controls and exon 30 mutant dermal 
fibroblasts  
A: Total TGFβ; B: Active TGFβ. The t-test was used for statistical analysis, error bars represent 
the standard error of the mean values (SEM). NS: non-significant. Controls (n=4); Patients 
(n=4). This experiment was performed once. 
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3.1.6 Non-canonical TGFβ signaling in exon 30 mutant cells 
We also tested for other non-canonical signaling pathway components including pJNK1, pP38 
and pERK to see if there were any changes in the activation of these molecules at the protein 
level. P38 and JNK1 phosphorylation were not changed between patient and controls under any 
treatment conditions (Figure 3.9). The level of pERK was slightly decreased in mutant cells 
under serum-free condition and upon TGFβ treatment (Figure 3.9B and Figure 3.9C), but no 
significant difference was observed in pERK between mutant cells and controls treated with 10% 
serum or a TGFBR1 inhibitor (Figure 3.9D).  
Overall, our results showed elevated canonical, but unaffected non-canonical TGFβ 
signaling despite unaltered extracellular TGFβ activity in exon 30-mutant cells, whereas cells 
with ELN mutations in exon 34 had normal TGFβ signaling. Our results indicate mutation-
specific TGFβ signaling changes in ELN-related cutis laxa patients.  
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Figure 3.9 Largely normal non-canonical TGFβ signaling in patients with exon 30 
mutations 
Immunoblotting of protein extracts from dermal fibroblasts under the following conditions: A-B: 
untreated (10% serum and serum-free), C: TGFβ1 stimulation for 90 min or D: TGFβ1 and 
TGFBR1 inhibitor for 90 min in patients with exon 30 mutations. Quantitative data normalized 
by the loading control are shown below the blots. NS: non-significant. Bar graphs show the mean 
± s.e.m. * P<0.05: obtained from t-test. C: controls (n=4); P: patients (n=4). This experiment was 
performed once. 
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3.1.7 The expression of TGFβ receptors at the protein and RNA levels 
To investigate if changes in TGFβ receptor expression could explain the increased TGFβ activity 
in ADCL fibroblasts, membrane proteins from 4 patients and 4 controls were extracted, and 
immunoblotting was performed using pTGFBR1, TGFBR1, TGFBR2, and TGFBR3. TGBFR1 
and pTGFBR1 levels were increased in ELN-mutant cells in both baseline conditions (Figure 
3.10A and Figure 3.10B) and remained increased relative to the controls upon TGFβ 
supplementation (Figure 3.10C). TGFBR1 inhibitor treatment abolished the in pTGFBR1 and 
TGFBR1 abundance (Figure 3.10D), suggesting abnormal auto-regulation of TGFBR1 in mutant 
cells. These findings were consistent with the increased SMAD2 phosphorylation levels under 
the same conditions. There was no significant difference in TGFBR2 and TGFBR3 levels 
between control and patients groups under any of the treatment conditions (Figure 3.10). Thus, 
elevated TGFβ signaling in exon 30 mutant cells was associated with increased levels of 
pTGFBR1 and TGFBR1, but not TGFBR2 or TGFBR3. 
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Figure 3.10 Increased pTGFBR1 and TGFBR1 abundance in patients with exon 30 
mutations 
A-B: Immunoblotting of membrane protein extracts from dermal fibroblasts left untreated (10%
serum and serum-free), C: treated with TGFβ1 or D: with TGFβ1 and TGFBR1 inhibitor.
Immunoblots were quantified by densitometry. Tubulin served as a loading control. pTGFBR1:
phosphorylated TGFBR1. Quantitative data normalized by the loading control are shown below
the blots. Bar graphs show the mean ± s.e.m. *: Statistically significant as demonstrated by p <
0.05 obtained with a t-test, NS: non-significant. C: controls (n=4); P: patient (n=4). This
experiment was performed once.
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Because we found increased TGBFR1 levels at the protein level, I wanted to test whether 
there is an enhanced TGBFR1 level at the mRNA level. Q-PCR was performed to measure the 
mRNA levels of TGFBR1 and TGBFR2 under baseline conditions. TGFBR1 mRNA levels were 
increased in mutant cells (Figure 3.11A) however, no significant difference was found in the 
expression of TGFBR2 levels in patients and controls (Figure 3.11B). 
Figure 3.11 Increased TGFBR1 mRNA levels in ADCL patients with exon 30 mutations 
Quantitative RT-PCR showed A: increased TGFBR1 mRNA expression in patients compared to 
controls. B: same TGFBR2 mRNA expression in patients and controls. Bar graphs show the 
mean ± s.e.m 3 biological replicates and 4 technical replicates. The reference gene was GAPDH. 
RNA expression levels were compared between controls and patients using unpaired t-tests with 
the p values shown above each graph. NS: non-significant. This experiment was performed once. 
A B
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3.1.8 Expression of TGFβ pathway components and target genes 
To further probe the activity of the TGFβ signaling pathway, I tested if there were any changes in 
the expression of key TGFβ pathway components and target genes. CTGF mRNA levels were 
slightly increased in patients with exon 30 mutations; however, there was no significant 
difference in the expression of TGFB1 and PAI1. SMAD6 and SMAD7 mRNA expression was 
decreased by about 50% in ADCL patients (Figure 3.12). 
Figure 3.12 Q-PCR analysis of CTGF, TGFB1, PAI1, SMAD6 and SMAD7 in patients with 
exon 30 mutations 
Data are means ± s.e.m of 3 biological replicates and 4 technical replicates. The reference gene 
was GAPDH. Unpaired t-tests were used to compare the expression levels of controls and 
patients. *: Statistically significant as demonstrated by p<0.05, NS: non-significant. This 
experiment was performed once. 
69 
3.1.9 Normalized allelic expression upon long-term TGFβ treatment 
A pilot experiment was performed to see whether TGFβ treatment affects the relative expression 
of wild-type and mutant alleles. No difference was found between WT and MT alleles upon 
TGFβ treatment in 30 min, 90 min, 4 hr, 8 hr and 24 hr when compared to untreated levels of 
WT and MT alleles (data not shown). These time periods might be too short to reflect the 
differences in the allelic expression, so I extended the TGFβ treatment time points to 1 day, 2 
days, 4 days, 10 days and 15 days. TGFβ treatment for 10 days resulted in normalized allelic 
expression in cell line 7159 (Figure 3.13), so I administered TGFβ to each of the the dermal 
patient fibroblasts for 10 days, which consistently normalized the expression of the mutant allele 
in each (Figure 3.14).  
Figure 3.13 A pilot experiment with different TGFβ treatment time points 
TGFβ was administered to patient cell line 7159 for 1 day, 2 days, 4 days, 10 days and 15 days 
and mRNA products of wild-type and mutant alleles were studied at each indicated time point 
using fluorescently labeled primers. The products were sized and quantified using a genetic 
analyzer and the Peak Scanner software. 
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Figure 3.14 Normalized allelic expression upon long-term TGFβ treatment 
A-G: Long-term TGFβ treatment normalized allelic imbalance in the expression. A-D: patients
with exon 30 mutations, E-G: patients with exon 34 mutations. mRNA products of wild-type and
mutant alleles were studied in each indicated individual using fluorescently labeled primers. The
products were sized and quantified using a genetic analyzer and the Peak Scanner software.
Allele intensities were normalized to average of the untreated wild type (WT) allele signals in
each sample. Data are means ± s.e.m of 3 biological replicates and 3 technical replicates in each
individual. WT allele intensity was compared to mutant (MT) allele intensity using unpaired 2-
tailed t-tests with the p values shown above each graph. NS:non-significant. This experiment was
repeated once with similar results.
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We also identified the relative expression of mRNA products of wild-type and mutant 
alleles in patients with exon 30 and exon 34 mutations in the elastin gene either untreated or 
TGFβ treatment (All patients showed four different mRNA isoforms: a normal full length 
mRNA, a shortened mRNA isoform missing exon 32 due to alternative splicing, a mutant full 
length mRNA and a mutant shortened mRNA isoform missing exon 32. Normal dermal 
fibroblasts expressed two mRNA isoforms as a result of alternative splicing of exon 32 (data not 
shown). Upon 10-day TGFβ treatment, we found an increase in the WT mRNA isoforms and a 
decreased MT mRNA isoforms (Figure 3.15). 
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Figure 3.15 Relative expression of ELN transcripts 
Relative expression of splicing products in patients with exon 30 and exon 34 mutations with and 
without TGFβ treatment. A-D: patients with exon 30 mutations, E-G: patients with exon 34 
mutations. mRNA products of wild-type and mutant alleles were studied in each indicated 
individual using fluorescently labeled primers. The products were sized and quantified using a 
genetic analyzer and the Peak Scanner software. Allele intensities were normalized to average 
wild type (WT) allele signals in each sample. Data are means ± s.e.m of 3 biological replicates 
and 3 technical replicates in each individual. Unpaired t-tests were used and *: statistically 
significant as demonstrated p<0.05; NS: non-significant. MT:mutant ; e32: exon 32. This 
experiment was performed once with similar results. 
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3.1.10 Improved elastin deposition in ADCL cells upon long-term TGFβ treatment related 
to increased cell number 
A pilot experiment was performed to see whether TGFβ affects the elastin deposition in ADCL 
cells. Dermal fibroblasts were subjected to TGFβ treatment for 1 day, 2 days, 4 days, 10 days 
and 15 days. We observed an increase in the number of patient cells upon TGFβ treatment; 
however, the number of control cells remained unchanged.  Based on the results, 10-day TGFβ 
treatment was chosen, which the TGFβ treated levels of elastin in a patient fibroblast reached the 
untreated levels of elastin in a control dermal fibroblast (Figure 3.16). 
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Figure 3.16 Pilot TGFβ treatment experiment with different time points in a patient with 
exon 30 mutation and a matched control. 
TGFβ was administered to a control (9175) and a patient (7159) dermal fibroblast for 1 day, 2 
days, 4 days, 10 days and 15 days. Cell numbers were counted by Cellometer Mini Cell Counter. 
Fastin elastin assay was performed to measure the elastin levels. Elastin concentration was 
normalized by cell numbers.  
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Ten day TGFβ supplementation enhanced elastin levels in controls and ADCL patients 
with exon 30 and exon 34 mutations (Figure 3.17A and Figure 3.17D). Parallel cell cultures were 
used to count the cells in untreated and TGFβ treated dermal fibroblasts. An increase was 
observed in the number of cells in ADCL patients, whereas no change was observed in cell 
numbers of control individuals (Figure 3.17B and Figure 3.17E). Normalization by cell numbers 
indicated that increased elastin deposition in ADCL cells was primarily caused by increased cell 
numbers, not increased elastin production per cell (Figure 3.17C and Figure 3.17F). 
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Figure 3.17 Improved elastin deposition in ADCL cells upon long-term TGFβ treatment 
related to increase cell number    
A,D: Fastin elastin assay was performed to measure the elastin levels  upon 10 day TGFβ 
treatment in ADCL with exon 30 and exon 34 mutations in the ELN and matched control 
fibroblasts. B,E: Cell numbers were counted using Cellometer mini cell counter in ADCL 
patients and controls. C,F: Elastin concentrations were normalized by cell number. Data are 
means ± s.e.m of 3 biological and 3 technical replicates in each individual. ** P<0.001 using the 
unpaired t-test, NS: non-significant. This experiment was performed once. 
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The long term TGFβ treatment also normalized the ELN mRNA levels in patients with 
exon 30 mutations and controls (Figure 3.18A) and caused more increase in ELN mRNA levels 
in patients with exon 34 mutations and controls ( Figure 3.18B). 
Figure 3.18 ELN mRNA expression levels in exon 30 and exon 34 patients upon 10-day 
TGFβ treatment 
A:  TGFβ normalized ELN mRNA expression in exon 30 patients and increased ELN mRNA 
expression in exon 30 patients. B: TGFβ treatment resulted in more increase in the ELN RNA 
expression in patients with exon 34 mutations and controls. Q-PCR data are means ± s.e.m of 3 
biological replicates and 4 technical replicates in each individual. The reference gene was 
GAPDH. Unpaired t-tests were used to compare the expression levels of controls and patients. 
 *: P<0.05, NS: non-significant. C: controls, P: patients. This experiment was performed once. 
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3.2 DISCUSSION 
In the present study, I investigated the possible molecular mechanisms and possible treatment 
strategies in ADCL. Results for exon 30 and exon 34 mutations are summarized in Table 3.4. 
Table 3.4 Comparison of results with patients with exon 30 and exon 34 mutations 
Results Exon 30 Exon 34 
Total ELN mRNA Decreased expression Increased expression 
Fragment analysis Increased abundance of 
mutant mRNA except 7002 
Increased abundance of 
mutant mRNA  
Elastin deposition Reduced elastin deposition in 
patients 
Reduced elastin deposition in 
patients 
Canonical TGFβ signaling Increased pSMAD2 and 
pSMAD3 
 No difference in pSMAD2 
between patients and controls 
Non-canonical TGFβ 
signaling 
No change in pJNK1 and 
pP38, decrease in pERK 
No change in pERK 
TGFβ activity No change in total and active 
TGFβ 
Expression of TGFβ receptors 
at the protein level 
Increase in pTGFBR1 and 
TGFBR1, no change in 
TGFBR2 and TGFBR3 
Expression of TGFβ receptors 
at the RNA level 
Increase in TGFBR1 and no 
change in TGFBR2 
Expression of TGFβ pathway 
components and target genes 
Increase in CTGF, no change 
in PAI1 and TGFβ1, decrease 
in SMAD6 and SMAD7 
Long term TGFβ treatment 
allelic expression 
Increased WT allele, 
decreased MT allele 
Increased WT allele, 
decreased MT allele 
Long term TGFβ treatment 
elastin deposition and cell 
number 
Improved elastin deposition 
related to increased cell 
number 
Improved elastin deposition 
related to increased cell 
number 
Long term TGFβ treatment 
total ELN mRNA 
Normalized ELN mRNA Further increase in ELN 
mRNA 
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3.2.1 ELN expression in ADCL cells 
I studied several aspects of the effect of ADCL mutations on ELN mRNA expression. Overall, 
ELN expression levels were similar was in ADCL cells to controls. However, modest differences 
were noted when ADCL cells were stratified by the location of the mutation. Cells with exon 30 
mutations had about 20% decreased, whereas cells with exon 34 mutations had about 20% 
increased ELN expression. The precise cause of this difference remains unclear, and may be 
related to spurious effects of incomplete matching and relatively low numbers of cases and 
controls. A possibly relevant difference is the presence of a mutant transcript isoform in cells 
with exon 30 mutations that includes a premature termination codon in exon 32 in the mutant 
reading frame and is subject to nonsense-mediated decay (Figure 3.19). In contrast, exon 34 
mutations are located in the last exon and are therefore not subject to nonsense-mediated decay 
(Figure 3.20). However, the abundance of the transcripts containing exon 32 may be too low to 
produce a noticeable difference in total ELN expression of cells with exon 30 mutations (Figure 
3.15). 
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Figure 3.19 Structure of WT and MT mRNA products in patients with exon 30 mutations 
Out of frame sequence is shown in red. WT, MT, WT-e32 and MT-e32 mRNA transcripts are 
shown. Note that when exon 32 is retained, it contains a premature termination codon in this 
frame (MT e32 in). However, when exon 32 is skipped as a result of an alternative splicing 
event, which occurs in 75% of the transcripts, reading frame 3 extends past the normal 
termination codon found in reading frame 1 (MT e32 out). 
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Figure 3.20 Structure of WT and MT mRNA products in patients with exon 34 mutations 
Out of frame sequence is shown in red. WT and MT mRNA products are shown. 
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I found significantly higher levels of mutant ELN mRNA in 3 of 4 ADCL cells with exon 
30 mutations and 3 of 3 cells with exon 34 mutations when compared to wild type ELN mRNA. 
These results uncovered a significant allelic imbalance, defined here as unequal expression of the 
wild-type and mutant alleles. In previous studies, increased abundance of stable mutant ELN 
mRNA in ADCL patients was noted (Callewaert et al., 2011), but was not analyzed 
quantitatively and statistically.  
The precise mechanism responsible for the marked allelic imbalance in ADCL remains 
unclear, but may be related to translational interference with miR29-mediated down-regulation 
of ELN mRNA stability. Mutations in both exon 30 and exon 34 result in frameshift mutant 
mRNA with the mutant reading frame extending past the normal termination codon and one of 
the three miR29 binding sites in the 3’-untranslated region (3’-UTR) (Figure 3.19). As active 
translation is known to interfere with microRNA activity (Gu et al., 2009), the extension of the 
mutant open reading frame is expected to increase the stability of the mutant mRNA, whereas the 
wild type transcript will remain subject to miR29-mediated down-regulation resulting in allelic 
imbalance.  
Given the previous data implicating dominant negative and toxic gain of function 
mechanisms in ADCL, I predict that the relative expression of mutant and wild-type alleles will 
have important implications for elastin biosynthesis and for disease outcomes. This prediction 
will have to be tested experimentally by assaying elastic fiber deposition in an experimental 
assembly system that allows the precise titration of the wild type and mutant tropoelastins. One 
such system is use of human retinal pigment epithelium cell line (ARPE19) in combination with 
exogenously supplemented recombinant tropoelastin (Wachi et al., 2005). The in vivo 
consequences of the relative expression of wild type and mutant alleles in ADCL can be studied 
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in mice carrying different combinations of knockout and transgenic elastin alleles (Hu et al., 
2010; Sugitani et al., 2012). To date, the results of these transgenic and knockout studies support 
the conclusion that disease outcomes in ADCL are very sensitive to the expression of both the 
mutant and wild type alleles.  
If clinical data can be collected from sufficient numbers of ADCL patients with without 
significant allelic imbalance, it will be possible to test the effect of this phenomenon directly in 
humans. In other autosomal dominant diseases, increased expression of mutant alleles is 
generally found to result in more severe presentation, as observed in familial cardiac 
hypertrophic cardiomyopathy (Tripathi et al., 2011).  
3.2.2 Impaired elastin deposition in ADCL cells 
Similar to previously published results (Callewaert et al., 2011), I observed significantly lower 
amounts of elastin deposited by all ADCL cells. The reduction in elastin deposition (33%) was 
somewhat greater in cells with exon 30 mutations compared to cells with exon 34 mutations 
(24%). This was expected based on the slightly reduced overall ELN mRNA expression in 
patients with exon 30 mutations and increased ELN transcript abundance in cells exon 34 
mutations. The observation of reduced elastin deposition irrespective an overall increase or 
decrease in ELN gene expression supports a dominant negative or toxic gain of function 
mechanism previously suggested for ADCL (Hu et al., 2010; Callewaert et al., 2011). 
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3.2.3 Altered TGFβ signaling in ADCL cells 
I observed increased pSMAD2 levels in ADCL patients with mutations in exon 30 dermal 
fibroblasts in two baseline conditions (10% serum and serum-free), consistent with previous 
findings in ADCL skin fibroblasts (Callewaert et al., 2011) and lung tissue in a transgenic mouse 
model of ADCL (Hu et al., 2010). SMAD2 phosphorylation levels remained elevated upon 
TGFβ treatment, but TGFBR1 inhibitor treatment abolished the difference in signaling between 
patient and control cells. Similarly, the other key signal transduction molecule within the 
canonical TGFβ signaling pathway, SMAD3, also showed increased phosphorylation under 
serum free and TGFβ supplementation conditions, which was also abolished by TGFBR1 
inhibition. These results suggest that increased canonical TGFβ signaling in ADCL is related to 
TGFβ receptor activity, not the availability of TGFβ.  
In contrast, all components of the non-canonical TGFβ signaling pathway were either 
unchanged (most conditions and signaling molecules) or decreased (pERK under serum free and 
TGFβ supplementation conditions). TGFBR1 inhibitor treatment also normalized pERK levels, 
suggesting that their decrease depended on TGFβ receptor levels. Therefore, we conclude that 
exon 30 mutations in ELN result in TGFBR1-dependent up-regulation of the canonical but not of 
the non-canonical TGFβ signaling pathway. A limitation of TGFβ signaling pathway 
experiments in ELN-mutant cells is that I only performed immunoblotting once. However, the 
results were consistent between experiments, and with previously published data. 
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Alteration of the extracellular matrix and consequent changes in the sequestration of 
latent TGFβ complexes may result in altered extracellular TGFβ activity, a possible explanation 
for the observed increase in intracellular signaling. However, three lines of evidence exclude this 
possibility: (i) TGFβ supplementation did not abolish the signaling differences, (ii) extracellular 
TGFβ activity and (iii) TGFB1 gene expression was equal in patients and controls. Conversely, 
the ability of TGFBR1 inhibitors to eliminate signaling differences suggested changes in 
TGFBR1 activity. Indeed, I found elevated TGFBR1 and pTGFBR1 protein levels and 
commensurately increased TGFBR1 mRNA levels in cells with exon 30 mutations. These 
findings support increased TGFBR1 gene expression as the likely mechanism for the signaling 
changes, possibly through altered feedback regulation of TGFBR1. The analysis of TGFβ target 
genes confirms this conclusion. The expression of both SMAD6 and SMAD7, known negative 
feedback regulators of TGFBR1 were significantly decreased explaining the increased TGFBR1 
levels in ADCL cells with exon 30 mutations. Consistent with increased transcriptional output of 
the TGFβ pathway, the expression of CTGF was increased in exon 30 mutant cells. However, 
upregulation of TGFβ targets does not appear to be uniform as the esxpression PAI1 was 
unchanged. More comprehensive gene expression analysis will be necessary to gauge the broad 
effect ADCL mutations on TGFβ target genes.  
Interestingly, patients with ELN mutations in exon 34 had normal TGFβ signaling, 
suggesting mutation-specific TGFβ signaling changes in ADCL. A relevant molecular difference 
between the exon 30 and 34 mutations is the length of the frameshift peptide sequence at the end 
of the encoded mutant proteins, which was shown to be correlated with the severity of unfolded 
protein response in ADCL cells (Callewaert et al., 2011). Recent studies on embryonic stem cells 
suggest that the UPR can enhance TGFβ signaling (Xu et al. 2014). Therefore, it is possible that 
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differences in UPR activation between exon 30 and exon 34 mutations can explain differential 
activation of the TGFβ pathway. 
ADCL is not the only type of cutis laxa with alterations in TGFβ signaling related to 
abnormal TGFβ receptor activity. In LTBP4-related cutis laxa (also known as autosomal 
recessive cutis laxa type 1C), despite elevated extracellular TGFβ activity, TGFBR1 and 
TGFBR2 are down-regulated at the protein level by endocytosis and lysosomal degradation (Su 
et al 2015). However, increased LTBP4-mediated stabilization is unlikely to be a mechanism for 
increased expression of TGFBR1 in ADCL cells with exon 30 mutations, because increased 
TGFBR1 expression was observed at both mRNA and protein levels and because the expression 
of TGFBR2 was not altered in ADCL cells.  
3.2.4 Increased TGFβ signaling as a compensatory mechanism 
A key question is whether the observed increase in canonical TGFβ signaling in ADCL patients 
with exon 30 mutations is contributing to the molecular pathology, is simply a molecular marker 
of the disease, or is a compensatory change ameliorating disease outcomes. To investigate these 
possibilities, I subjected ADCL cells to long-term TGFβ treatment and quantified overall ELN 
mRNA levels, allelic expression and elastin deposition. For each of these variables, TGFβ 
treatment produced an improvement: it increased overall ELN expression while increasing the 
contribution of the wild type and reducing the contribution of the mutant allele and increased the 
overall deposition of elastin. Therefore, I conclude that increased TGFβ signaling in ADCL 
patients with exon 30 mutations is a compensatory molecular mechanism.  
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TGFβ is known to up-regulate ELN expression by both transcriptional (Kuang et al., 
2007; Oleggini et al., 2008) and post-transcriptional (Kahari et al., 1992; Kucich et al., 1997) 
mechanisms. Thus, increased ELN expression upon TGFβ treatment was expected. Differential 
regulation of the wild type and mutant alleles by TGFβ was more surprising, but can be 
explained by invoking the same mechanism I proposed for the observation of allelic imbalance in 
ADCL cells: interference of frameshift mutations with the binding of miR29 in the 3’-UTR of 
ELN. As TGFβ is a negative regulator of miR29 expression (van Rooij et al, 2008), it up-
regulates ELN expression by removing inhibition by miR29. The absence of miR29 in TGFβ-
treated cells would eliminate differential regulation of mutant vs. wild type transcripts resulting 
in equal allelic expression, as I observed.  
TGFβ treatment also increased elastin deposition in both in patients with exon 30 and 
exon 34 mutations and controls. The TGFβ treated in ADCL fibroblasts deposited approximately 
the same amount of elastin as untreated in control cells. Interestingly, TGFβ treatment resulted in 
enhanced cell proliferation in patients, but it did not cause any changes in cell proliferation in 
control cells. The precise mechanism to explain why TGFβ treatment increases cell proliferation 
in ADCL but not in control cells remains unknown. However, one expects increased cell density 
to augment elastin deposition. It is also unclear if altered allelic expression contributes to 
increased elastin deposition in TGFβ-treated ADCL cells, or if increased cell density is sufficient 
to explain it. One of the limitations of this experiment is that we only tested the cell proliferation 
and elastin deposition in monolayer skin fibroblast cultures. It remains to be shown if long term 
TGFβ treatment is beneficial to disease outcomes in vivo. Therefore further studies will be 
required in animal models such as zebrafish or mice with ADCL-like mutations. These future 
studies will be essential to determine if approaches to augment TGFβ signaling are beneficial for 
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the treatment ADCL patients. Given the pleiotropic nature of TGFβ, possible concerns with 
extended treatment include risks of developmental, fibrotic or immunological anomalies.  
3.2.5 Conclusions 
In conclusion, my results showed a series of interesting molecular mechanisms relevant to 
ADCL in general or to certain subgroups of mutations in particular. I found invariably elevated 
expression of the mutant allele in ADCL cells, which could be suppressed by long-term TGFβ 
treatment. Long term TGFβ treatment was also beneficial in normalizing elastin deposition by 
ADCL cells, partly by selectively increasing ADCL proliferation and possibly by balancing 
allelic expression. In addition, I found elevated TGFβ signaling in ADCL cells with exon 30 
mutations but not in cells with exon 34 mutations. Given the beneficial effects of TGFβ 
treatment on elastin deposition and allelic expression, I conclude that elevated TGFβ signaling in 
in ADCL cells with exon 30 mutations is a compensatory mechanism. More broadly, differential 
stabilization of mRNA products of mutant and wild type mRNAs is an as yet unexplored avenue 
of therapeutic intervention for autosomal dominant diseases. 
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4.0  A PARTIAL ELASTIN GENE DUPLICATION IN SUPRAVALVULAR AORTIC 
STENOSIS 
4.1 RESULTS 
4.1.1 An SVAS family with a partial ELN gene duplication 
A 3-generation SVAS family (Figure 4.1) with microarray data showing a duplication of an 
approximately 80 kb region spanning the promoter region, the exon 1 and intron 1 of ELN was 
referred to us for further genetic and functional analysis. The mother and 3 children had the 
duplication, and the father was unaffected. Matching dermal fibroblasts were selected for SVAS 
patients (Table 4.1). 
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Figure 4.1 A pedigree of a SVAS family with a duplication in the ELN gene 
Individuals with samples available to study are numbered.  
Table 4.1 SVAS patients and control cells used in the study 
Patient Age (years) Sex Passage number 
1224 37 Female 6 
1226 5 Female 4 
1227 3 Female 4 
1228 3 Female 4 
1225 38 Male 6 
9215 9 Female 4 
9068 4 Female 4 
9176 9 Female 4 
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4.1.2 Expression analysis of the duplication 
I tested whether a tetranucleotide repeat in intron 1 (Urban et al., 1997) fell within the duplicated 
region. Although 2 alleles were found for each individual within the family (Figure 4.2, Table 
4.2 and Table 4.3), the quantitative analysis indicated double dose for the maternal, mutant allele 
(259) in all affected children confirming that the duplication encompasses this polymorphism
(Figure 4.2A-C). Quantitative analysis showed a 3-fold increase in mutant pre-mRNA expression 
compared to wild type (Figure 4.2D-F) consistent with active transcription of both duplicated 
copies.  
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Figure 4.2 Increased relative dose and relative expression of the mutant allele in affected 
individuals 
Genotyping for a tetranucleotide repeat in intron 1 was performed on genomic DNA (gDNA) and 
cDNA from fibroblasts of each indicated individual using fluorescently labeled primers. The 
products were sized and quantified using a genetic analyzer and the Peak Scanner software. 
Allele intensity data were normalized to the average of wild type (WT) allele intensities in each 
sample. Data are means ± s.e.m of 3 replicates. Mean allele intensities were compared to mutant 
allele (MT) using unpaired t-tests with the p-values shown above each graph. This experiment 
was repeated once with similar results.  
A B C
D E F
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To monitor the expression of the non-duplicated part of the mutant elastin gene, I 
searched for SNPs heterozygous in affected individuals. Following genotyping 9 SNPs, one, 
located in intron 23 (rs28763986) was found to be heterozygous in all affected individuals at the 
DNA level (Figure 4.3, Table 4.2). The T allele was linked to the wild type, and the C allele was 
linked to the mutant allele. RT-PCR and sequencing showed a lack of expression of the mutant 
allele at the pre-mRNA level (Figure 4.3). Taken together, my expression data indicate that the 
duplicated region of the mutant elastin gene as expressed whereas the non-duplicated region is 
transcriptionally silent. Thus, I conclude that this duplication results in a null allele. All RNA 
samples were tested for DNA contamination by amplifying “No RT” control samples with 
negative results (Figure 4.4). 
Table 4.2 Genotyping of genetic markers in gDNA 
SNPs Location RefSNP 
Alleles 
1224 1225 1226 1227 1228 
rs4556939 Exon 1 A>G AA AA AA AA AA 
rs884843 Intron 1 A>G AA AG AA AA AA 
rs868005 Intron 1 A>G AA AG AA AA AA 
Tetranucleotide repeat 1 Intron 1 (CCTT)n 259/259 263/270 259/263 259/263 259/263 
rs4717865              Intron 4       A>G               AA AA AA AA AA 
rs41500150 Exon 5 G>T TT TT TT TT TT 
rs20062910 Exon 14 A>C AA AA AA AA AA 
rs2071307 Exon 20 A>G GG AG GG GG GG 
rs28763986 Intron 23 C>T CT TT CT CT CT 
rs17855988 Exon 26 C>G GG GG GG GG GG 
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Table 4.3 Genotyping of informative markers in cDNA 
SNPs Location RefSNP Alleles 1224 1225 1226 1227 1228 
rs28763986 Intron 23 C>T TT TT TT TT TT 
Tetranucleotide 
repeat 1 
Intron 1 (CCTT)n 259/259 263/270 259/263 259/263 259/263 
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Figure 4.3 SNP(rs28763986) is heterozygous at the DNA level and homozygous at the pre-
mRNA level in affected individuals 
DNA sequencing was performed on genomic DNA (gDNA) or cDNA samples isolated from 
fibroblasts of each numbered individual in the pedigree. Heterozygous samples are marked by 
boxed bases above the corresponding sequence traces. Haplotype information is shown for each 
sample in the pedigree for the duplication, tetranucleotide repeat and rs28763916. Maternal WT 
(259) allele is shown in red and maternal MT (259) allele is shown in blue. Paternal WT (263)
allele is shown in green and paternal WT (270) allele is shown in purple.
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Figure 4.4 A gel image showing genomic DNA and RT-PCR results with no RT and no 
template controls 
PCR was performed on gDNA, cDNA, No RT and No template samples isolated from dermal 
fibroblasts of each indicated individual. rs28763986, which is located in intron 23 of the ELN 
gene was amplified.  
4.1.3 Reduced elastin deposition in patients 
To test whether the null allele caused by the duplication affects the amount of elastin deposited 
by the SVAS cells, I quantified it using the Fastin Elastin Assay (Biocolor). I found about 21% 
of reduction in elastin in SVAS fibroblast cells compared to controls consistent with previous 
reports of reduced elastin production in SVAS cells (Urban et al., 2002) (Figure 4.5). 
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Figure 4.5 Elastin quantification showed a significant decrease in patient fibroblasts  
Fastin elastin assay was performed to measure the soluble elastin from SVAS and matched 
control fibroblasts. Data are means ± s.e.m of 4 replicates. * P<0.05 using the paired one-tailed 
student’s t-test. This experiment was performed once. 
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4.2 DISCUSSION 
I conducted several functional studies and to solve the exact nature of an 80 kb duplication which 
includes exon 1 of the elastin gene and part of the upstream sequences in an SVAS family. 
Analysis of a tetranucleotide repeat polymorphism in intron 1 suggested that it was within the 
duplicated region and expressed from both the maternal and paternal alleles in children. 
Quantitative analysis showed double dose for the mutant allele and a 3-fold increase in mutant 
mRNA expression in all affected children. All possibilities for the duplication type of SVAS 
family are shown in Figure 4.6. Tandem duplications are expected to result in 3-fold increased 
expression of the mutant allele compared to the wild type because both copies of the duplicons 
are expected to be transcribed from the upstream promoter with an additional copy transcribed 
from the downstream promoter. In contrast, pre-mRNA from a 5’ inverted duplication is 
expected to produce a 2-fold increase and a 3’ inverted duplication a 4-fold increase. Because I 
observed 3-fold increase in mutant allele expression compared to wild type, my data supports the 
presence of a tandem duplication (Figure 4.6).  
For a more direct characterization of the duplication, the breakpoint regions will need to 
be sequenced. Although I attempted to PCR across the breakpoints to clone and sequence them, a 
high density of repetitive DNA around the breakpoint region made difficult to achieve this goal. I 
did the primer walking and genomic PCR to amplify the breakpoint region, however none of the 
sequences gave ELN sequence. My findings provide some insights about whether the duplication 
is inverted or tandem, however, the exact duplication breakpoints needs to be further analyzed. 
For example multiplexed direct genomic selection (MDiGS) methodology coupled with deep 
sequencing (Alvarado et al., 2014) could be used to identify the breakpoints and confirm the 
orientation of the duplicons. 
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Figure 4.6 Possible duplication types in SVAS patients 
Arrows indicate the direction of the promoters in each duplicon. The duplicated region of the 
gene is shown in red.  
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I looked at intronic variants and genotyped genomic DNA and RT-PCR products from 
pre-mRNA. I found a SNP (rs28763986), located in intron 23, which was heterozygous in all 
affected family members at the DNA level, but the mutant allele was not expressed at the pre-
mRNA level. Overall, our results suggest the duplication led to a null allele. Additionally, I 
found reduced levels of elastin in affected individuals compared to controls, which is consistent 
with the previous studies (Urban et al., 2002). 
SVAS is most commonly caused by point mutations located in the 5’-end and middle part 
of the ELN gene leading to nonsense mediated decay (Urban et al, 2000), however, frameshift 
mutations in the 3’end of the ELN gene result in extended reading frames (Tassabehji et al. 1998; 
Zhang et al., 1999) and ADCL. The molecular mechanism of SVAS mutations is 
haploinsufficiency, while the molecular mechanism of ADCL mutations is dominant negative or 
toxic gain-of-function. A large intragenic deletion has been identified in a family with SVAS 
(Olson et al. 1995), whereas a large duplication resulting in the synthesis of a mutant protein has 
been described in a family with cutis laxa (Urban et al. 2005). This is the first duplication shown 
to cause SVAS to date, but the lack of expression of the non-duplicated part of the mutant gene 
is consistent with the haploinsufficiency mechanism of all SVAS mutations studied to date. More 
research is needed to find out whether there is an overlap in the mutational spectrum of 
associated with SVAS and ADCL. 
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5.0  CONCLUSION 
ECM has several functions consisting cell-cell communication, cell proliferation, development 
and the regulation of the bioavailability of TGFβ. Elastic fibers provide elastic stretch to the skin 
tissue. Elastin is the major component of elastic fibers and it is secreted as a tropoelastin from 
fibroblasts, vascular smooth muscle cells (SMCs), endothelial cells and chondroblasts. Elastin 
gene mutations result in several diseases including WBS, SVAS and ADCL. Several 
mechanisms have been identified as result of ELN mutations in these disorders; however, the 
understanding of these mechanisms remains incomplete. 
We found a decreased ELN mRNA expression in patients with exon 30 mutations and an 
increased ELN mRNA expression in patients with exon 34 mutations. Overall, we found 
relatively unchanged ELN expression in all patients with exon 30 and exon 34 mutations. 
Examining the relative expression of MT and WT ELN alleles in fibroblasts from 7 individuals 
with ADCL, we observed 1.5-2-fold increased expression of mutant alleles at the mRNA level. 
In table 3.4, I summarized the results for each mutation group. Treatment of mutant fibroblasts 
with TGFβ for 10 days yielded an increase in the expression of WT alleles, but a decrease in the 
expression of the MT alleles, abolishing the differences in allelic expression. TGFβ1 treatment 
also normalized the amount of insoluble elastin deposited by ADCL cells (Figure 5.1). 
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Figure 5.1 A summary model for elastic fiber assembly in ADCL cells in untreated and 
TGFβ treated conditions 
A: More mutant elastin in untreated condition interferes with orderly deposition of wild type 
elastin onto microfibrils , B: TGFβ treatment increases wild type elastin more than the mutant 
and also increases the production of other elastic fiber components to increase elastin deposition.  
Patients with exon 30 mutations had increased canonical TGFβ signaling and normal 
non-canonical TGFβ signaling (Figure 5.2 and Figure 5.3). Our results suggested increased 
TGFβ signaling is a significant compensatory mechanism ameliorating the molecular 
consequences of ADCL mutations. On the other hand, patients with exon 34 mutations had 
normal TGFβ signaling suggesting mutations-specific TGFβ signaling changes in ELN-related 
cutis laxa (Figure 5.4). 
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Figure 5.2 Canonical TGFβ signaling pathway in patients with exon 30 mutations 
Under baseline conditions (serum and serum-free), SMAD2 and SMAD3 phosphorylation was 
increased. Extracellular levels of TGFβ remained unchanged. TGFBR1 and pTGFBR1 levels 
were increased; TGFBR2 and TGFBR3 levels remained unchanged. SMAD6 and SMAD7 levels 
were decreased. CTGF gene expression levels were increased and PAI1 gene expression levels 
remained unchanged. 
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Figure 5.3 Non-canonical TGFβ signaling pathway in patients with exon 30 mutations 
pJNK1 and pP38 levels were unchanged, whereas pERK levels were decreased in patients with 
exon 30 mutations. 
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Figure 5.4 Canonical and non-canonical TGFβ signaling pathway in patients with exon 34 
mutations 
Patients with exon 34 mutations had normal canonical and non-canonical TGFβ signaling. 
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Overall, my results shed light into establishing new connections between elastin 
biosynthesis and growth factor signaling and emphasize the contribution of increased mutant 
allele to the molecular disease mechanisms in ADCL and support TGFβ1 augmentation as a 
possible therapeutic approach. 
Genetic and functional analysis of SVAS also contributed to the molecular mechanisms 
of elastinopathies. I identified a tetranucleotide repeat in intron 1 and a SNP in intron 23 to be 
heterozygous in affected individuals. Gene dosage analysis showed that the tetranucleotide 
repeat 1 was within the duplicated region. The primary treatment for SVAS is the vascular 
surgery with higher risk of morbidity and mortality. More research is needed to find out the 
cellular and molecular mechanisms of SVAS and discover new therapeutic strategies to prevent 
morbidity and mortality. In general, studies on elastinopathies can inform the understanding and 
treatment approaches to the some common diseases such as aortic aneurysms, arterial stenoses 
and emphysema. 
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APPENDIX: SUPPLEMENTARY TABLES AND FIGURES 
 
Table S.1 Primers genotyping for SVAS 
 
SNPs  Name of primers Primers sequence 
(5’3’) 
Tm (°C) 
 rs884843  hELNi1-1s 
hELNi1-1a 
CAGACCAGGCTCTTCAGC 
CCTATGTTGCCCAGGCTG 
 
55.6 56.1 rs868005  hELNi1-1.2s 
hELNi1-1.2a CTGGTCTGAATTCCTGGG GACCACACGAAGCTGTTG  52.4 54.3 rs2071307  elhELN-i19-1s 
elhELN-i21-1a GTGCTAGGATTACAGGCATG CTCGTGACCTTGGTCCAG  53.1 55.2 rs28763986  elhELN-i21-1s 
elhELN-i23-1a GAAGGTGCCAGGAAGCCA CCCACACTCCTAGAGGTC  57.9 53.8 
rs17855988 elhELN-i23-1s 
elhELN-i26-1a CTGATCCAGGGTCACACAG CAGATGCTTAGGAGAACC  55.5 49.5 rs41500150 elhELN-i4-1s 
elhELN-i5-1a  GACACCTGCACTGCACAT CTTCCTCCATGCAGCCTTC 55.7 56 rs20062910 elhELN-i13-1s 
elhELN-i15-1a GGTGACAGGTGCAGACTC GGATACATGGATGCATGG  55.5 50.4 rs4556939 hELNei5-1s 
hELNei1-1a CTTGTGAGCCGGGCCTTTC GAGGACCCAGTGGCTGAG  59.1 57.7 rs4717865 hELNi4-1s 
hELNi4-1a GTAGAGCTAGGTTCCCAG GTTGCCTTGTCCTGTTCCTA  51.3 55.7 
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Table S 1 Continued 
Tetranucleotide 
repeat 1 
Outside primers 
hELNi1.11s 
hELNi1.11a 
Inside primers 
5’-FAM-hELNi1.3s 
hELNi3.1a 
GAGAAAAGTAAATGGGGCC
A 
AATCACCACCTCCAAATGCT 
5’-
/FAM/GCCCACATGGGCAGA
TTGCT 
CCCTCATCCACAGACAGGTC 
52.8 54.6 61 57.2 
Mycoplasma Myco-S 
Myco-A 
TGCACCATCTGTCACTCTGTT
AACCTC 
GTGGGAGCAAACAGGATTAG
ATACCCT 
60.1 59.9 
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Figure 5.5 Electrophereograms of some patient and control samples 
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Table S 2 Identify testing by microsatellite analysis 
 
Markers 1224 1225 1226 1227 1228 
CSF1PO 10,12 10,12 10,12 12 10,12 
D2S1338 20,20 20,25 20,25 20,20 20,20 
D3S1358 16,17 15,18 15,17 16,18 16,18 
D5S818 10,11 12,16 11,15 11,12 11,12 
D7S820 10,11 10,11,12 10,11,12 10 10,11 
D8S1179 11,12 13,14 11,14 12,13 9,12 
D13S317 12,13 9,11,12 9,11,12 11,12 10,12 
D16S539 11,13 11,12 11,12 11 11 
D18S51 12,13 16,16 12,16 - 12 
D19S433 13,14 12,14 13,14 12,14 12,14 
D21S11 27,30 30,32.2 27,30 30,32.2 30,32.2 
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